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Parts of the data obtained from this work has led to a publication in the 
Virus-Cell Interactions section of the January 1990 issue of Journal of Virology 
(Rasty, S., Dhruva, B.R., Schiltz, R. L., Shih, D. S., Issel, C. J., and Montelaro, R
C. 1990. Proviral DNA integration and transcriptional patterns of equine 
infectious anemia virus during persistent and cytopathic infections. J. Virol., in 
press).
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ABSTRACT
The transcriptional properties of equine infectious anemia virus were 
examined in two distinct equine cell lines in which the virus establishes either a 
persistent or a cytopathic infection. Northern hybridization analyses were 
performed to determine the number, sizes, and relative levels of the EIAV 
transcripts encoded during persistent or cytopathic infections. Three species of 
viral mRNA were detected in infected cells: an 8.2-kb full-length genomic mRNA, 
a 3.5-kb single-spliced mRNA, and a low abundance 1.5-kb mRNA, presumably 
formed by a double-splicing event of the full-length mRNA. Analysis of the levels 
of EIAV-specific RNA’s present during persistent and cytopathic infections has 
revealed that quantitative differences characterize the transcriptional patterns of 
EIAV in these two infections. In persistently infected FEK cells the 8.2- and 3.5- 
kb mRNA’s are the predominant viral transcripts and are detected in 
approximately equal concentrations, while the 1.5-kb mRNA is detected at very 
low levels. During the cytopathic infection of FDD cells, however, the 3.5-kb 
mRNA is the predominant viral transcript, comprising nearly 75% of the total 
viral mRNA, while the 8.2- and 1.5-kb mRNA’s constitute the remaining 25% of 
viral transcripts. Moreover, the cytopathic infection is characterized by almost a 
thirty-fold higher level of viral transcripts than those detected during the 
persistent infection.
The splicing patterns of the full-length EIAV mRNA during the cytopathic 
infection were determined by cDNA cloning and sequencing, Northern 
hybridization analyses using splice donor-specific oligonucleotide probes, and SI
nuclease mapping of RNA from virus-infected cells. The results have identified 
the splice donor and acceptor sites used to generate the spliced mRNA’s of EIAV 
in infected cells.
The expression of a putative regulatory protein of EIAV from a structural 
viral gene was investigated by analysis of in vitro and in vivo expression products. 
In vitro transcription and translation along with in vivo expression in transfected 
COS-7 cells were used to analyze the expression of the viral env gene. Based on 
the results of these studies, a potential mechanism for co-expression of two 
separate proteins from the env mRNA is proposed.
x
CHAPTER 1 
INTRODUCTION
EQUINE INFECTIOUS ANEMIA: THE DISEASE
Persistent retrovirus infections constitute a major challenge in 
contemporary human and veterinary medicine. With the discoveries of 
retroviruses associated with human leukemia and acquired immunodeficiency 
syndrome (AIDS), the urgency to develop preventative or therapeutic measures 
against these types of viral infections has become increasingly more apparent. To 
understand the patterns of retrovirus gene expression and to make correlations 
with viral pathogenesis, it is essential that animal systems be developed to serve 
as models for human retroviruses, where experimental infections are not possible.
Equine infectious anemia (EIA) is a naturally occuring worldwide disease 
of horses caused by a nononcogenic retrovirus (Charman et al., 1976; Cheevers et 
al., 1977; Issel and Coggins, 1979). EIA, or swamp fever as it is known 
colloquially, has been recognized as a viral disease of horses since the early 
1900’s when it was shown to be caused by a filterable viral agent (Vallee and 
Carre, 1904). Each year in the United States nearly 700,000 horses are tested for 
EIA, and the highest incidence of the disease is reported to be in Louisiana. 
Although known as a viral disease for over eighty years, significant progress 
toward understanding the disease at the cellular and molecular level has only 
been accomplished within the last decade.
1
2Clinical Signs of EIA
One of the features distinguishing EIA from other retrovirus-induced 
diseases is its episodic nature and variable clinical course (Crawford et al., 1978; 
Issel and Coggins, 1979; Orrego et al., 1982). Following infection, the disease is 
characterized by unpredictable bursts of plasma viremia, recurring peaks of fever 
above normal animal temperatures, and cycles of clinical symptoms which occur 
in sequential episodes that are separated by several weeks or months. Horses 
developing the clinical signs of EIA are described to exhibit acute, chronic, or 
inapparent cases of the disease (Issel and Coggins, 1979), as depicted in Figure 1.
Acute EIA. This stage of the disease is most often associated with the 
animal’s first exposure to the virus and is a result of massive virus replication in 
infected macrophages. At this stage of the disease the virus is believed to cause a 
lytic infection of macrophages (Kono, 1969; McGuire et al., 1971) leading to their 
eventual destruction. Most horses with acute EIA survive the infection and may 
go unnoticed since the classical signs of the disease such as weight loss, anemia, 
or edema are not usually evident at this stage.
Chronic EIA. The more classic clinical signs of EIA, such as weight loss, 
anemia, and ventral edema are exhibited by the infected animal at this stage of 
the disease. In these animals the characteristic recurrent cycles of illness are 
observed, the frequency and severity of which usually decline with time. In 
addition to the above symptoms, infected horses may also exhibit lathargy, 
leukopenia, depression of central nervous system, fever, and hemorrhages (Orrego 
et al., 1982).
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Figure 1. Schematic representation of the different stages of EIA in infected 
horses.
Inapparent EIA. A high percentage of infected horses exhibit no clinical 
illness and are inapparent carriers of virus. These animals, although asymptomatic 
and healthy appearing, harbor the virus for life and virus or viral products can be 
detected in blood of such animals (Kemen and Coggins, 1972; Issel et al., 1982). 
Therefore these inapparent carriers pose a serious threat in spreading the disease 
to normal uninfected horses.
The variable clinical course of EIA depends in part on resistance factors of 
the host, viral virulence factors, and environmental stresses (Issel and Coggins, 
1979). Following the initial infection, the animal may develop chronic EIA with 
its characteristic recurrent disease episodes, or in some cases the infection may 
lead to an initial febrile attack, after which the animal may remain asymptomatic 
for the remainder of its life. Such apparently normal horses may suddenly re­
experience an acute febrile episode. Moreover, such inapparently infected animals 
may be induced to experience clinical EIA by exposure to certain environmental 
stresses such as hard work, or upon injection with immunosuppressive drugs (Issel 
and Coggins, 1979).
Transmission
Natural transmission of EIA is mainly horizontal and rarely vertical. It 
usually occurs through the transfer of blood from the infected horse by 
interrupted blood feeding of hematophagous insects, such as horse flies or deer 
flies (Issel and Coggins, 1979; Williams et al., 1981; Foil and Issel, 1982; Foil et 
al., 1983, 1984; Issel et al., 1988). Virus may also be transmitted to an uninfected 
horse by the transfer of blood or blood products on contaminated instruments or
5syringes (Issel and Coggins, 1979). Although the virus can be demonstrated in 
excretions and secretions of acutely infected horses, there is no evidence of the 
natural contact transmission of the virus. In all types of transmission, it appears 
that an infected donor exhibiting the clinical signs of EIA has a greater potential 
of transmitting the virus when compared to one showing no signs of disease. This 
observation is apparently correlated with the level of virus in the donor’s blood 
and tissues. The virus can apparently cross the placental barrier and be 
transmitted to the fetus. Mares with signs of acute EIA during pregnancy seem to 
have the greatest potential for carrying infected fetuses (Kemen and Coggins, 
1972), although more than 75% of the foals born from infected mares appear to 
be free of EIA (Kemen and Coggins, 1972; Foil and Issel, 1982).
Diagnosis
As a clinical disease, EIA can often be diagnosed on the basis of history 
and clinical signs of the affected animal. Since clinical signs of EIA are not 
always definitive, specific laboratory tests are helpful in the diagnosis of the 
disease. Such tests normally involve the detection of virus or EIA-specific 
antibody in the animal.
The horse inoculation test (Issel and Coggins, 1979) is by far the most 
direct method developed to date for demonstration of circulating virus in the 
blood of an infected horse. It is performed by injection of blood taken from a 
suspected horse into an uninfected host. Development of clinical disease in the 
recipient horse conclusively demonstrates the presence of virus in the donor. The 
main drawback with this procedure, however, is that it is expensive, time
6consuming, and the results may be unclear as it is often difficult to interpret the 
clinical illness in the recipient horse as a definitive sign of EIA in the donor 
animal.
A variety of serological tests have also been developed and used for 
diagnosis of EIA. These include the complement fixation test (Kono and 
Kabayashi, 1966), the serum neutralization test, and the agar gel immunodiffusin 
(AGID) test, popularly known as the Coggins test (Roth et al., 1971; Coggins et 
al., 1972). The AGID test is based on the detection of EIA-specific antibody in 
the serum of the suspected animal and is a reliable and sensitive test for EIA. 
The correlation between AGID-seropositivity and the presence of infectious virus 
in the blood of the animal being tested has been documented to approach 100% 
(Coggins, 1972). However, as with any other serologic test based on antibody 
detection, the AGID test does not detect the presence of dormant virus in an 
infected animal with very low levels of virus-specific antibody or the phase of 
infection prior to antibody production.
Other serological tests, usually more sensitive than the AGID test, 
including immunofluorescence (Crawford et al., 1971), radioimmunoassay 
(Coggins et al., 1978), enzyme-linked immunosorbent assay (ELISA) (Shane et al., 
1984), and competitive ELISA (C-ELISA) (Hussain et al., 1988) have also been 
used for detection of EIA-specific antibody.
The more sensitive serological tests for EIA have become important in 
diagnosis of EIA in cases when the AGID titers are extremely low. However, the 
guidelines established by the United States Department of Agriculture (USDA)
7for diagnosis of EIA-positive horses are currently introducing certain barriers in 
the use of such tests. The USDA standard for diagnosis of EIA requires that a 
horse be either: (1) AGID test-positive, or (2) horse inoculation test-positive, or 
(3) both (Issel et al., 1988). There are inherent problems in diagnosis of EIA- 
positive horses which do not have a high enough virus titer in their blood to 
transfer the infection to a recipient horse in a standard horse inoculation test, but 
are diagnosed as EIA-positive using the more sensitive ELISA tests. However, 
such antibody-positive "virus-negative" horses are currently being released from 
USDA restrictions as "false-positive" animals (Issel et al., 1988). Such potential 
transmitters of EIA pose a great threat to the healthy normal horse population. 
Therefore, the urgent need for the development of a more accurate set of 
standards for EIA detection cannot be overemphasized. Accordingly, more 
definitive methods of diagnosis designed to detect the presence of actively 
replicating virus in the blood or tissues of a test animal rather than EIA-specific 
antibody need to be developed. In this regard diagnostic ELA tests based on the 
polymerase chain reaction (PCR) (Scharf et al., 1986; Mullis and Fallona, 1987; 
Saiki et al., 1988), which would detect viral genetic material in the suspected 
animal, would have a great potential in the near future. To date there has been 
no known treatment or preventative measures developed for EIA. Efforts to 
control this economically important disease have mainly involved screening for 
EIA-positive horses and subsequent spatial separation of these carriers from 
normal healthy horses during housing and transportation.
EQUINE INFECTIOUS ANEMIA VIRUS: THE CAUSATIVE AGENT
Equine infectious anemia virus (EIAV), the causative agent of the disease 
equine infectious anemia, is a member of the retrovirus subfamily of RNA 
viruses. Retroviruses are unusual entities in that they propogate themselves by 
taking advantage of the lifestyles of their host animals in unique and 
unprecedented ways. They convert their genes from RNA to DNA, incorporate 
the DNA intermediate stably into chromosomes of somatic or germ cells, and 
often times mutate or even capture cellular genes. Many retroviruses rarely 
impair and often potentiate the growth of their host cells, and all retroviruses 
express their genes by using host-specific mechanisms and machinery under the 
direction of viral genetic control signals. These viruses have been isolated from a 
diverse group of vertebrate animals including mammals, birds, and reptiles 
(Teich, 1982, 1985), and can cause a wide array of oncogenic, nononcogenic, and 
progressive diseases. The common taxonomic features of retroviruses are 
summarized in Table I.
Subfamilies of Retroviuses
On the basis of cross-reactivity of the group-specific major antigen within a 
subfamily, genomic organization, morphological data, and in part, the 
characteristics of the disease the virus induces in the infected animal, the family 
of retroviruses are divided into three subfamilies: oncoviruses, spumaviruses, and 
lentiviruses.
Table L Taxonomic characteristics common to retroviruses.0
Morphology
Spherical enveloped virions (80 to 120 nm in 
diameter); variable surface projections (8 nm); 
icosahedral or cubic capsid containing a 
ribonucleoprotein complex.
Physiochemical properties
Density 1.16 to 1.18 g/ml in sucrose, 1.16 to 
1.21 g/ml in cesium chloride; sensitive to lipid 
solvents, detergents, and heat inactivation; 
highly resistant to UV and X-ray irradiation.
Nucleic acid
About 1% by weight; linear single-stranded 
positive-sense RNA (60 to 70 S) composed of 
two identical subunits (30 to 35 S).
Protein^
About 60% by weight; gag-encoded internal 
structural proteins (3 to 5); po/-encoded 
reverse transcriptase, protease, and integrase 
(2 to 3); env-encoded envelope structural 
proteins (1 to 2).
Lipid
About 35% by weight; derived from the 
infected cell's membrane.
Carbohydrate
About 4% by weight; associated 
predominantly with env proteins.
a. From Teich (1982), and Bharat Parekh, Ph.D. 
dissertation, Louisiana State University, 1983.
b. The numbers in parentheses indicate the number of 
corresponding polypeptides.
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The oncovirus subfamily includes the oncogenic and serologically related 
nononcogenic retroviruses and replication-defective non-infectious oncoviruses. 
Oncoviruses, recognized for their cancer-causing potential, have been isolated 
from a wide variety of vertebrates such as fish, chickens, rodents, cats, and 
primates, and induce various tumors of mesenchymal origin (sarcomas), 
leukemias, and less often, epithelial malignancies including carcinomas of the 
breast, kidney, and liver (Weiss et al., 1982, 1985). Representative members of 
oncoviruses include the avian leukemia and sarcoma viruses, the murine leukemia 
and sarcoma viruses, bovine and feline leukemia viruses, and Mason Pfizer 
monkey virus. In addition, Human T-cell leukemia viruses type I and II (HTLV-I 
and HTLV-II) have also been tentatively placed in this subfamily (Poiesz et al., 
1980; Sonigo et al., 1981; Kalyanaraman et al., 1982).
Spumaviruses, commonly referred to as "foamy" viruses, are characterized 
by induction of foamy degeneration of infected cells in tissue culture. These 
viruses have been isolated from a number of mammalian species such as cattle, 
hamsters, rabbits, cats, monkeys, and humans (Gelderblom and Frank, 1987) and 
establish persistent infections with no evidence of pathogenesis. Representative 
members of this subfamily include simian foamy virus, bovine syncytial virus, and 
human syncytium-forming virus.
The lentivirus subfamily derives its name from the slow time course of the 
infections its members cause in their hosts. Lentiviruses cause chronic infections 
characterized by prolonged incubation periods of several months to many years, 
followed by a protracted symptomatic disease phase. The unifying theme among
11
lentivirus infections is the restricted viral gene expression in the host animal and 
persistent, latent infections that are not usually apparent for long periods of time 
(Haase, 1986). Among the chronic diseases which lentiviruses cause in animals 
are those affecting the lungs, joints, nervous, hematopoietic, and immune systems 
of humans and animals.
Although the classification of a retrovirus in this subfamily has traditionally 
been more heavily based on the progressive nature of the induced disease than 
on group-specific major antigen cross-reactivity, more recently retroviruses have 
been added to this subfamily based on nucleotide sequence homology and the 
organization of their genome (Gonda et al., 1985; Sonigo et al., 1985). Members 
of the lentivirus subfamily include the visna-maedi virus, progressive pneumonia 
virus (PPV), and caprine arthritis encephalitis virus (CAEV) of sheep and goats, 
equine infectious anemia virus (EIAV) of horses, feline immunodeficiency virus 
(FIV) of cats, bovine immunodeficiency virus (BIV) of cows, simian 
immunodeficiency virus (SIV) of monkeys, and the causative agent of acquired 
immunodeficiency syndrome (AIDS) in humans, the human immunodeficiency 
virus type 1 and type 2 (HIV-1 and HIV-2). EIAV was originally classified as a 
lentivirus due to its morphology and the chronic, persistent nature of its induced 
disease in horses (Charman et al., 1976; Parekh et al., 1980; Montelaro et al., 
1982), although no serological relatedness could be documented between this 
virus and the prototype lentivirus, visna virus (Stowring et al., 1979). However, 
recent determination of the EIAV nucleotide sequence and its genomic 
organization has provided clear evidence for the remarkable relatedness of this
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virus to other lentiviruses such as visna, CAEV, and HTV (Chiu et al., 1985; 
Rushlow et al., 1986; Stephens et al., 1986), thus substantiating its classification as 
a lentivirus. Moreover, recent serological studies have provided further evidence 
for the close relationship among the viruses of this subfamily by demonstrating 
that anti-HIV rabbit serum exhibits cross-reactivity with the BIV p26, CAEV p27, 
and ELAV p26 core proteins (Casey et al., 1985; Gonda et al., 1987). 
Physiochemical Properties of EIAV
ELAV has been shown to possess many of the physiochemical properties 
common to enveloped viruses in general and retroviruses in particular. Mature 
EIAV particles are enveloped and have a buoyant density of about 1.16 g/ml in 
cesium chloride (Matheka et al., 1976; Cheevers et al., 1977). Viral infectivity is 
sensitive to reagents which disrupt the lipid envelope such as detergents or ether, 
but is resistant to trypsin treatment, ultraviolet, and X-ray irradiation (Nakajima, 
1972). Moreover, treatment with certain chemical disinfectants such as sodium 
hydroxide, sodium hypochlorite, organic phenolic compounds, and chlorohexidine 
has been shown to inactivate virion infectivity (Shen et al., 1977).
The virus particle contains a 60 to 70S RNA genome composed of two 
identical single-stranded 34S subunits that are noncovalently bound near their 5’- 
ends, a virus-encoded RNA-dependent DNA polymerase (reverse-transcriptase) 
with optimal endogenous activity in the presence of Mg+ +, and a host-derived 
lysine-specific tRNA molecule whose 3’-end is hydrogen-bonded to an 18-base 
sequence (primer binding site, PBS) near the 5’-end of each genomic RNA
subunit (Charman et al., 1976; Archer et al., 1977; Cheevers et al., 1977; Varmus, 
1982; Stephens et al., 1986).
Virus Morphology
The morphological properties of retroviruses have been investigated by 
electron microscopy (Bernhard et al., 1958; Gross, 1970; Vigier, 1970). By virtue 
of minor differences revealed by electron microscopy, retroviruses can be divided 
into four morphological groups: type-A, type-B, type-C, and type-D (Bernhard, 
1960; Sarkar et al., 1972; Fine and Schochetman, 1978). These differences are 
related to the presence or absence of visible intracellular or extracellular viral 
particles, location of the inner core within the viral envelope, and changes in the 
morphology of the virion particles during the process of budding from the cell 
membrane.
Morphologically, EIAV exhibits characteristics consistent with that of most 
retroviruses. Electron microscopy studies have revealed spherical virion particles 
of 80 to 120 nm in diameter, with a rod- or cube-shaped electron dense nucleoid 
of about 40 to 60 nm in length (Weiland et al., 1977; Teich, 1982). The virus 
particle is bounded by a double-layered lipid envelope with spike-and-knob 
surface projections of about 6 to 8 nm in diameter (Nakajima et al., 1969; Tajima 
et al., 1969; Weiland et al., 1977). Mature EIAV particles acquire their envelope 
from the plasma membrane of the host cell during the budding process 
(McConnell et al., 1977; Gonda et al., 1978).
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Structural Components of EIAV
Experiments performed to identify viral structural proteins by guanidine 
hydrochloride gel filtration (GHCL-GF) and high resolution sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE), along with localization 
studies for determination of the organization of these polypeptides within the 
virion have provided the basis for understanding the structure of the intact EIAV 
virion (Montelaro et al., 1982; Parekh et al., 1980). In gel filtration 
chromatographic analysis of the cell-adapted Wyoming strain of EIAV 
radiolabeled with radioactive leucine or glucosamine, six distinct peaks of 
radioactivity, representative of virus-associated proteins, have been observed 
(Parekh et al., 1980). These proteins exhibit apparent molecular weights of 
100,000, 74,000, 26,000, 15,000, 11,000, and 9000. SDS-PAGE analysis of EIAV 
has revealed four major low molecular weight polypetides, designated p26, pl5, 
p ll , and p9, and six minor components. The minor components have been shown 
to include two glycosylated proteins of 90,000 and 45,000 molecular weight, 
designated gp90 and gp45, respectively, and four minor nonglycosylated proteins 
designated as p70, p61, p30, and p23. The unrelatedness of the four major 
nonglycosylated proteins (p26, pl5, p ll, and p9) have been demonstrated by 
comparative peptide mapping and enzyme-linked immunosorbent assays 
(Montelaro et al., 1982). Furthermore, biochemical characterization of these four 
nonglycosylated proteins of EIAV (Montelaro et al., 1982) has revealed that p26 
and p9 focus at isoelectric points (pi) of 6.2 and 5.0, respectively, and that they 
contain no unusual amino acids. The EIAV pl5 was shown to display a
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heterogeneous isoelectric focusing pattern with a pi ranging from 5.7 to 8.3, which 
could be attributed to different levels of phosphorylated serine or threonine or 
both. Finally, p l l  was observed to focus at a pi of greater than 10.0, suggesting 
its high content of basic amino acids. Among the two major glycoproteins of 
EIAV, gp90 is the more glycosylated polypeptide, while gp45 aggregates in 6 M 
guanidine hydrochloride, indicative of a hydrophobic nature (Parekh et cd., 1980).
Localization studies aimed at assigning the relative location of the virion 
polypeptides have been performed by treatment of purified virus with the 
protease bromelain. Such an analysis distinguishes surface proteins from those 
sequestered by the viral lipid bilayer from enzymatic digestion (Mosser et cd., 
1975). Applicaton of these studies to EIAV have revealed that gp90 and gp45 
constitute the surface proteins of EIAV, whereas p26, pl5, p ll, and p9 form the 
internal virion components. Furthermore, treatment of purified EIAV with 
Nonidet P-40, which releases the viral ribonucleoprotein complex, has shown that 
the highly basic EIAV p l l  is closely associated with the viral RNA genome 
(Montelaro et al., 1982).
Retroviral Genome: Structure, Integration, and Replication
The single most important feature which separates retroviruses from other 
animal viruses is their mode of replication. The very name "retrovirus" embodies 
the biological phenomenon which this family of viruses is most famous for: the 
ability to copy their single-stranded RNA genome into a double-stranded DNA 
intermediate in a multistep process coined as "reverse transcription". In fact, it 
was the pioneering work with these viruses which originally convinced the
scientific community of the "provirus hypothesis" (Temin, 1964, 1976); that 
transfer of genetic information in biological systems is not limited to the 
conventional processes of replication (DNA to DNA or RNA to RNA), 
transcription (DNA to RNA), and translation (RNA to protein).
As mentioned before, the viral genome is wrapped and securely protected 
in a core of viral protein which, in turn, is surrounded by a lipid envelope derived 
from the membrane of the previous host cell and containing viral glycoproteins. 
The infecting virion attaches to its target cell through an interaction with cell 
surface receptor proteins that are specifically recognized by viral envelope 
glycoproteins (Tardieu et al., 1982). Entry of the virus particle into the cell is 
probably mediated by receptor-mediated endocytosis, a mechanism that cells have 
evolved to ingest beneficial extracellular substances such as growth factors (Mims, 
1986).
Although replication of the extracellular virion particle occurs only within 
cells and depends on cellular functions and machinery, the infecting virus brings 
with it an organized collection of viral enzymes and RNA to direct its replication 
process. Following entry into the cell, the quiescent enveloped virion is uncoated 
and becomes an enzymatically active nucleoprotein complex capable of 
performing its initial programmed functions with little or no help from the host 
cell. Each viral genomic RNA molecule is base-paired with a specific, host cell- 
derived transfer RNA molecule that primes viral DNA synthesis during reverse 
transcription. Once the genomic RNA is copied into DNA by the virus-coded 
reverse transcriptase, the nucleoprotein complex migrates into the nucleus and
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mediates the covalent integration of the double-stranded DNA copy of the viral 
genome into the chromosomal DNA of the host cell. A schematic view of this 
replication cycle is presented in Figure 2 (Varmus, 1983).
Following the integration of its provirus, the retrovirus becomes totally 
dependent on its host cell for replication of the integrated provirus as a part of 
the cellular chromosome, for transcription of the proviral DNA by RNA 
polymerase II, for post-transcriptional processing of viral RNA transcripts by the 
host capping, polyadenylation, and splicing machineiy, and for translation of the 
resultant messenger RNA’s by the host’s ribosomes. Recognition signals, one of 
which may be localized in the leader sequences near the 5’-end of the viral 
genomic RNA (Shank and Linial, 1980; see below), then draw together the newly 
synthesized viral genomic RNA and core proteins from the cytoplasm and 
envelope glycoproteins embedded in the plasma membrane. A virus-encoded 
protease cleaves the viral polyproteins into the smaller functional components, 
and mature progeny virions are then released from the plasma membrane of the 
host cell. Figure 3 shows a schematic representation of the molecular events 
involved during the replication of the virion particle during the retroviral life 
cycle (Varmus, 1988).
Retroviral Gene Expression
Within the retrovirus particle, the genome is a complex of two identical 
RNA strands. Such a state of diploidy and genetic redundancy is a property not 
seen in other animal viruses and is unique to retroviruses, although its advantages 
are not well understood (Varmus, 1982, 1983, and 1988). Starting from the 5’-end,
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Figure 2. A simplified schematic representation of the various stages involved in 
reverse transcription. 1. Viral genomic RNA. R5 and R3: 5’- and 3’-direct 
terminal repeats; U5 and U3: 5’- and 3’-untranslated regions; PB: primer binding 
site; G,P, and E: gag, pol, and env genes, respectively. 2 and 3. First-strand cDNA 
and double-stranded DNA synthesis. 4. Circular double-stranded proviral DNA. 5. 
Integration of proviral DNA into host genome. 6. Transcription of proviral DNA 
to yield viral mRNA’s.
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Figure 3. The molecular events involved in the retroviral life cycle. Cap, capped 
nucleotide at the 5’-end of viral genomic RNA; A„ , poly(A) tail at the 3’-end of 
viral genomic RNA; R, direct repeat sequence at each end of viral RNA; U3 and 
U5, unique sequences duplicated during reverse transcription; LTR, long terminal 
repeat; gag, coding region for viral nucleocapsid proteins; pol, coding region for 
RNA-dependant DNA polymerase (reverse transcriptase); env, coding region for 
viral envelope proteins; CJ, circle junction where the ends of linear viral DNA 
are joined together; SD and SA , splice donor and acceptor sites, respectively; Psi, 
signal for packaging of viral RNA; P and CHO, post-translational modifications of 
viral proteins by phosphorylation and glycosylation, respectively. (From Varmus, 
1988).
V ir u s
p a r t i c l e
gag pol env 
Cap § a  Virion subunit
'  IR U5
Free DNA
 { 11=
gag pol env
O h —  Provirus 
S D |  SA '>
Psi I ^  env
I C a p  |  A n
vwwvw
W W W AM W W W
*
W A  MW W W \
S p l i c e
V W W W W A
*
AMWA M W
CHO
Genome
+
mRNA
Viral 
h proteins
22
as presented schematically in Figure 4, the arrangement of the noncoding 
sequences on the RNA molecule has the following features (Varmus, 1983):
A. The 5 ’-Cap. Similar to the S’-termini of almost all eukaryotic mRNA’s, 
an inverted 7-methylguanyl nucleotide (the "cap" nucleotide) is present at the 5’- 
end of the viral RNA.
B. The R Sequence. In addition to the genetic redundancy of retroviruses in 
having two identical genomic RNA’s, each RNA subunit is itself terminally 
redundant and carries at each end a direct repeat sequence of about 10-80 
nucleotides sequence (Coffin, 1979; see below). This sequence, termed R, plays 
an important role during the process of reverse transcription, and is present as a 
component of each long terminal repeat (LTR) sequence at the 5’- and 3’-ends of 
the proviral DNA (see below).
C. The U5 Sequence. Following the R sequence, a sequence of about 80- 
100 nucleotides, referred to as U5, is present at the 5’-end of the viral RNA. This 
sequence occurs only once in the viral RNA, but is present twice in the proviral 
DNA as a segment within the 5’- and 3’-LTR’s.
D. The Primer Binding Site (PBS). The initiation site for synthesis of the 
first strand of viral DNA during reverse transcription is the 3’-boundary of U5, 
which in turn is the site at which the host-derived tRNA primer is hydrogen- 
bonded to the viral RNA (Taylor, 1977). This sequence, usually 18 nucleotides 
long, is known as the primer binding site (PBS).
E. The Leader Region (L). Following the PBS, and preceding the 
translational initiation codon of the first structural gene (gag), is a sequence of a
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Figure 4. Anatomy of a genomic RNA subunit of a replication-competent 
retrovirus. The important structural and genetic domains of a typical single- 
stranded RNA subunit (about 8- to 9-kb) of a replication-competent retrovirus 
are indicated by the following notations: cap, 5’-cap nucleotide; R, terminal 
redundancy; U5, sequence unique to the 5’-terminus, present twice in vial DNA; 
(-)PB, binding site of primer, a host tRNA, for (-)DNA strand synthesis; L, leader 
region; Sj), splice donor site; SA, splice acceptor site; gag, pol, and env, coding 
regions for viral nucleocapsid proteins, reverse transcriptase, and envelope 
proteins, respectively; NT, nontranslated region between env and U3; (+)P, 
polypurine tract, primer for (+)DNA strand synthesis; U3, sequence unique to 
the 3’-terminus, present twice in viral DNA; A „ , poly(A) tract at the 3’-terminus. 
For clarity, terminal regions are shown at a 10X expanded scale. Lengths of the 
various regions are approximate and vary among different retroviruses. (From 
Varmus, 1983).
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few hundred nucleotides referred to as the leader (L) region. In addition to 
containing splice donor sites for generation of the spliced viral mRNA’s in many 
retroviruses, the L region may also contain the signal which facilitates packaging 
of viral RNA into virion particles (Shank and Linial, 1980).
F. The 3’-NT. The portion of the noncoding region downstream of the env 
gene which does not overlap with the U3 and R regions of the 3’-LTR is termed 
3’-NT. This region is variable in length among different retroviruses and lacks 
substantial open reading frames. A stretch of purine-rich nucleotides, directly 
preceding the U3 boundary and about 10-20 bases long, is located at the 3’- 
terminus of the 3’-NT and is a highly conserved feature among retroviruses. This 
purine-rich tract plays an important role during reverse transcription and appears 
to serve as primer for the synthesis of plus strand viral DNA.
G. The U3 Sequence. Analogous to the U5 sequence at the 5’-end of the 
viral RNA, the U3 sequence is the unique sequence which appears once at the 3’- 
end of the RNA molecule and twice in the proviral DNA as a component of each 
LTR. Within the LTR unit, an inverted repeat is present as a result of the first 5 
to 23 nucleotides of U3 being inversely repeated at the 3’-end of U5. Ranging in 
size from about 170 to 1250 nucleotides among different retroviruses, the U3 
sequence also varies greatly in length among different isolates of a single 
retroviral strain (Ju et al., 1980; Shimotohno and Temin, 1982; Van Beveren et 
al., 1982). The U3 sequence, although long enough in certain retroviruses to be 
considered as a potential protein coding domain, is analogous to the 3’-NT region 
in being usually devoid of open reading frames. The major function of the U3
25
sequence involves the regulation of synthesis and processing of viral RNA (see 
below).
H. The Poly (A) Tail. Added to the 3’-end of the viral RNA post- 
transcriptionally, presumably by cellular polynucleotide synthetases, is a poly(A) 
tail of about 100-200 nucleotides long. Since the poly(A) sequence is added to the 
RNA after its synthesis, its copy is not present in the proviral DNA template and 
is not reverse transcribed during the synthesis of viral DNA.
During the intricate process of reverse transcription, sequences present 
once at the 5’- and 3’-ends of the genomic RNA (U5 and U3, respectively) are 
duplicated to generate the long terminal repeat (LTR) sequences at the 5’- and 
3’-ends of the proviral DNA. The LTR unit, schematically presented in Figure 5, 
is several hundred bases in length and is a fusion of the sequences characteristic 
of the 3’-end of viral RNA (U3), the R sequence, and sequences characteristic of 
the 5’-end of viral RNA (U5), in the order 5’-U3-R-U5-3 (Varmus, 1983). The 
LTR provides the important regulatory sequence information required for 
expression of the viral genome, namely, signals for promotion, initiation, and 
polyadenylation of the viral transcripts. The U3 region of the LTR lies 
immediately upstream of the initiation site for viral RNA synthesis (Varmus and 
Swanstrom, 1982); approximately 25-30 nucleotides upstream from the 5’-end of 
R and within U3 retroviral LTR’s invariably possess the consensus 'TATAA box" 
sequence, strongly implicated in initiation of transcription by eukaryotic RNA 
polymerase II (Breathnach and Chambon, 1981). The 5’-end of R, also known as 
the cap site, is by definition the 5’-end of the viral RNA and is thus the
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Figure 5. Anatomy of an LTR. The figure shows the important features of the 
U3, R, and U5 sequences of the retroviral LTR and its flanking viral sequence. 
Features pertaining to a 5’-LTR are shown at the top of the figure, and those 
relevant to a 3’-LTR are presented at the bottom. The viral sequence at the 5’- 
boundary of U3 is the sequence of the putative primer for plus-strand DNA 
synthesis, and the sequence at the 3’-boundary of U5 is the binding site for the 
tRNA primer for minus-strand DNA synthesis. The LTR terminates with short 
inverted repeats (IR). The integration sites are usually 2-bp from each boundary. 
The sequences resembling CCAAT and TATAAA regulate the initiation of viral 
RNA synthesis from the cap site, while the non-overlapping sequence, usually 
AATAAA, determines the polyadenylation (A„) site at the 3’-end of RNA. (From 
Varmus, 1983).
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transcriptional initiation site (Varmus and Swanstrom, 1982; Varmus, 1983). A 
sequence resembling CCAAT is also usually found about 30-40 nucleotides 
upstream of the 'TATAA box" in the U3 region. The consensus eukaryotic signal 
for polyadenylation, AATAAA (Proudfoot and Brownlee, 1974; Fitzgerald and 
Shenk, 1981), is usually located near the 3’-end of U3, about 20 nucleotides 
upstream from the site of poly(A) additon (Varmus, 1982). In retroviruses with 
large R sequences the poly(A) addition signal can occur within R and must 
apparently be ignored during transcription from the 5’-LTR (Varmus, 1983). The 
dinucleotide CA, usually defining the R-U5 boundary, also serves as the 
polyadenylation site on the RNA molecule (Bonner et al., 1982; Chen and Barker, 
1984).
The coding sequences within the retroviral genome contain at least three 
genes, located in between the two LTR units, which encode the structural and 
replicative components of the virus particle. These genes are gag, encoding the 
viral core proteins or group-specific antiens; pol, encoding the viral RNA- 
dependent DNA polymerase (reverse transcriptase), integrase, and protease; and 
env, encoding the viral envelope proteins.
Certain retroviruses possess additional genes which code for proteins with 
specialized intracellular functions, such as oncogenes or regulatory genes. A group 
of oncoviruses, typified by Rous sarcoma virus (RSV), carry a viral oncogene 
whose product is directly involved in the swift induction of tumors in animals and 
the efficient transformation of cells grown in culture (Bishop and Varmus, 1982). 
On the other hand, HTLV-I and -II, also recognized as oncoviruses, promote
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their oncogenic action through the product of a small open reading frame that 
lies between the viral env gene and the 3’-LTR. This protein acts as a positive 
effector of transcription from the viral LTR and from certain cellular promoters, 
thus promoting tumorigenesis (Sodroski et al., 1984; Greene et al., 1986; Seiki et 
al., 1986). Moreover, a common feature among lentiviruses, which is absent in 
oncoviruses, is the presence of several small open reading frames (ORF’s) in their 
genomes in addition to the structural and replicative gag, pol, and env genes 
(Ratner et al., 1985; Sanchez-Pescador et al., 1985; Sonigo et al., 1985; Wain- 
Hobson et al., 1985; Rushlow et al., 1986). These short ORF’s, usually located 
between the pol and env genes and near the 3’-end of the env gene, have been 
intensely studied within the past few years and have invariably been shown to 
encode regulatory proteins which act as either positive or negative effectors of 
viral gene expression (see below).
As mobile genetic elements within eukaryotes, retroviruses have evolved 
into complex entities which have adopted a combination of devices and 
mechanisms to facilitate their expression in host cells that normally operate in a 
totally different pattern of genetic organization. In eukaryotic cells, genes are 
principally arranged as single coding sequnces that are interrupted by noncoding 
regions (introns or intervening sequences). Retroviruses, however, are composed 
of multicistronic genomes destined to be expressed in eukaryotic cells, which are 
normally not equipped to translate several independent genes from a single 
mRNA. To get around this problem, retroviruses have evolved two specific 
strategies of gene expression: production of spliced subgenomic mRNA’s from a
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single full-length viral mRNA in order to provide the coding message for proteins 
encoded at internal positions of the viral genome; and cleavage of the primaiy 
viral translational products (polyproteins) to generate multiple functional proteins 
required for viral replication.
Synthesis and Splicing of the Full-Length Viral mRNA
The primary product of transcription from the proviral DNA template 
initiates at the 5’-boundaiy of the R sequence within the 5’-LTR, to which then 
the 5’-cap nucleotide is added post-transcriptionally (Varmus, 1983). Although this 
primary transcripts, hereafter referred to as the full-length viral mRNA, is 
approximately the same length as the subunit of viral genomic RNA, there is 
evidence to believe that transcription can extend some distance beyond the 3’-end 
of the R sequence, copied from the 3’-LTR and to which the poly(A) tail is 
added (Yamamoto et al., 1980; Ucker, 1981; Nevins, 1982).
Since the coding region for the env gene lies in the 3’-half of the genomic 
RNA, its translation from the full-length viral mRNA requires a splicing event in 
which the gag-pol intron is removed from this primary transcript, joining 5’-leader 
sequences to the env coding sequences (Varmus and Swanstrom, 1982). The splice 
donor site for this splicing event usually resides in the leader region downstream 
of the transcriptional initiation site and upstream of the gag open reading frame, 
although there are exceptions to this rule in certain retroviruses, such as RSV, in 
which the donor site lies within the gag gene (Hacket et al., 1982). The splice 
acceptor site is usually located just upstream of the env open reading frame, thus
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allowing the fusion of the 5’-leader and env sequences through the two splice 
junction signals.
As mentioned above and presented in detail below, relative to other 
retroviruses, lentiviruses possess additional smaller regulatory genes near the 3’- 
end of the env gene or within the pol-env intergenic region. In many cases studied 
to date (Arya et al., 1985; Arya and Gallo, 1986; Davis et al., 1987; Muesing et al., 
1985; Rosenblat et al., 1988), these regulatory genes are encoded by multiple 
small exons encoded within short open reading frames (ORFs) in the 3’-half of 
the genome. Generation of mRNA’s for these small coding sequence usually 
occurs through multiple splicing events by which both the gag-pol and the env 
introns are spliced out of the full-length viral mRNA to generate a small mRNA, 
usually 1.2-2.0 kb in length and composed of 5’-leader sequences fused to the 
small exons of the regulatory gene, to allow for the translation of the regulatory 
mRNA.
Translation of the Viral mRNA’s
The full-length viral mRNA serves as the message for synthesis of a gag- 
pol precursor polyprotein which is then post-translationally modified and 
processed to yield the mature viral core proteins and reverse transcriptase (Vogt 
and Eisenman, 1973; Vogt et al., 1975). The mechanism used for the synthesis of 
the gag-pol fusion protein illustrates the unique and intricate strategies evolved by 
retroviruses to utilize the eukaryotic cellular machinery. The gag and pol genes 
are separated by a nonsense termination codon at the 3’-end of gag in MLV; they 
read in different and briefly overlapping frames in RSV and all lentiviruses such
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as HTV, visna, and EIAV; and are separated by a third open reading frame (pro, 
which stands for the viral protease) in MMTV, BLV, and HTLV-II (Varmus,
1988). Rather than directing the host cell’s splicing machinery to splice out the 
gag stop codon or to create monocistronic messages by splicing out pol sequences 
from the full-length viral mRNA, retroviruses instead take advantage of the 
potential of eukaryotic ribosomes to occasionally insert an amino acid in place of 
the termination codon at the 3’-end of the MLV gag (Yoshinaka et al., 1985) to 
suppress translational termination, or to utilize the occasional frameshifting of 
eukaryotic ribosomes at defined sites and frequencies in order to bypass the gag 
termination codon in RSV, HIV, MMTV, BLV, and HTLV-II (Jacks and Varmus, 
1985; Jacks et al., 1987; Moore et al., 1987, Jacks et al., 1988). To date, these 
phenomena have not been observed in translation of cellular mRNA’s and would 
indeed be deleterious if occurring frequently and without any control mechanism. 
However, their occurence have clear advantages for retroviruses in that structural 
(gag) proteins can be synthesized in large quantities required for viral replication, 
while catalytic (pol and pro) proteins not required to be made in large amounts 
can be synthesized in relatively small quantities. With this translational 
mechanism, pol products destined to be packaged into progeny virion particles 
can also be directly incorporated into the viral core through attached gag 
components.
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The Lentivirus Genomic Organization: Trans-acting Factors and Cis-acting 
Sequences
As mentioned before, a common feature among lentiviruses, which is 
absent in oncoviruses, is the presence of several small open reading frames 
(ORFs) in their genomes in addition to the structural and replicative gag, pol, 
and env coding sequences. In general, these short ORFs encode tram-acting 
regulatoiy proteins which act as either positive or negative effectors of viral gene 
expression. The complex regulation of lentivirus gene expression, brought about 
by the fine tuning of these regulatory genes, is believed to enable these viruses to 
establish latency within the infected host, then respond rapidly to various signals 
to synthesize high levels of viral proteins leading to active viral replication 
(Peterlin et al., 1988).
The genomic organization of several representative lentiviruses, including 
EIAV, are presented in Figure 6. Among lentiviruses, the most intensely studied 
virus within the past five years has been HTV-1, and much has been learned 
about the molecular biology and genetic complexity of this virus. HIV-1 and HIV- 
2 are very similar and the two viruses share a 50-60% similarity in their primary 
proviral DNA sequence (Clavell et al., 1986; Ho et al., 1987; Fauci, 1988).
The HTV-1 genome encodes at least three genes, tat, rev, and nef, whose 
products regulate viral gene expression. The coding sequences for tat, or trans- 
activator of transcription, are within two separate exons of the HTV genome 
(Figure 6) which are brought together a double-splicing event of the full-length 
HTV-1 mRNA (Arya et al., 1985; Sodroski et al., 1985). The tat gene product of
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Figure 6. The genomic organization of representative lentiviruses. In addition to 
the gag, pol, and env genes, lentiviruses possess additional short open reading 
frames in between pol and env and near the 3’-terminus of env. These additional 
ORF’s in HIV-1 code for virion infectivity factor (vif), viral protein R (vpr), trans- 
activator of transcription (tat), regulator of expression of virion proteins (rev), 
viral protein U (vpu), and negative factor (nef). The HIV-2 and SIV genomes 
similarly encode vif (vip or virion infectivity protein in the case of SIV), vpr, tat, 
rev, and nef, but do not code for vpu. Instead, HTV-2 and SIV contain an ORF 
for viral protein X (vpx). Of the three short ORF’s of EIAV, SI, S2, and S3, only 
SI is currently known to encode a regulatory protein (see text).
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HIV-1 is a 14-kda protein containing a stretch of cysteine residues followed by a 
stretch of basic amino acids, both of which are required for its activity (Arya et 
al., 1985; Sodroski et al., 1985; Arya et al., 1987). Moreover, the tat protein forms 
a non-covalently linked dimer which binds divalent cations in solution (Frankel et 
al., 1988) and is localized in the nucleus (Hauber et al., 1987). Mutations and 
deletions in the tat gene have been shown to abolish viral infectivity, thus tat is 
essential for HIV-1 replication (Dayton et al., 1986; Fisher et al., 1986; Luciw et 
al., 1987). The cis-acting element on the HIV-1 genome required for tat activity is 
a tram-acting response sequence (TAR), originally defined as the region from 
positions -17 to +80 within the 5’-LTR (Rosen et al., 1985). Additional 
mutational analysis of TAR has revealed that only sequences from +19 to +42 
are required for responsiveness to tat (Jacobovits et al., 1988; Peterlin et al.,
1988). Although not precisely defined, the mechanism of fram-activation by tat 
has been suggested to involve transcriptional, post-transcriptional, and 
translational events. The regulatory function(s) of tat have been related to an 
increase in steady-state levels of RNA species containing the TAR element at 
their 5’-ends (Cullen, 1986; Peterlin et al., 1986; Wright et al., 1986; Kao et al., 
1987; Muesing et al., 1987), a bimodal mechanism involving two sites of action, 
one leading to increased levels of TAR-containing RNA’s and the other to even 
higher levels of their encoded protein products (Cullen, 1986; Wright et al., 1986), 
and an increase in the rates of initiation (Jacobovits et al., 1988; Laspia et al.,
1989) and elongation (Kao et al., 1987; Laspia et al., 1989) of transcription from 
the 5’-LTR. More recently, tat has been shown to interact with the RNA
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sequence of TAR, rather than its DNA sequence (Berkhout et al., 1989), giving 
rise to speculations that it might function as an RNA enhancer (Sharp and 
Marciniak, 1989). In general, the interaction of tat with TAR-containing RNA is 
believed to facilitate transcriptional elongation, increase mRNA stability, and 
enhance translation. The predominance of each effect might then depend on 
quantitative differences in tat and qualitative differences in host cellular factors 
(Peterlin and Luciw, 1988).
rev, or the regulator of expression of viral proteins, previously known as 
art/trs (the anti-repression fro/is-activator/fra/is-regulator of splicing), is another 
trans-acting HIV gene product and its coding sequences overlap but are in a 
different reading frame from those of tat (Figure 6) (Sodroski et al., 1986; 
Feinberg et al., 1986). Similar to tat, mRNA coding sequences for rev are within 
two separate exons on the HIV genome which are brought together by RNA 
splicing. The rev gene product is a 19-kda protein which, like tat, contains basic 
residues and is localized in the nucleus (Cullen et al., 1988). The os-acting 
repression sequences (crs) in the full-length and single-spliced HIV-1 mRNA’s, 
encoding gag and env structural proteins, respectively, have been shown to render 
these long mRNA’s very unstable (Rosen et al., 1988). A separate as-acting anti­
repression sequence {car), located within env and non-overlapping with crs, is the 
target for the trans-acting rev protein (Felber et al., 1989; Hammarskjold et al., 
1989; Malim et al., 1989; Rosen et al., 1988). By interacting with car, also known 
as the rev-response element or RRE (Malim et al., 1989), the rev protein has been 
shown to directly effect the post-transcriptional processing of HIV-1 transcripts by
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activating the transport of full-length and single-spliced HIV-1 mRNA’s to the 
cytoplasm and away from the splicing machinery in the nucleus (Felber et al., 
1989; Hammerskjold et al., 1989; Malim et al., 1989). By so doing, at the expense 
of viral regulatory proteins being expressed from the double-spliced viral 
mRNA’s, including rev itself, rev rescues and exports incompletely spliced HIV-1 
gag and env mRNA’s away from the nucleus for translation of viral structural 
proteins in the cytoplasm.
nef, or the negative factor, previously known as 3'-orf, orfB, E \  and F, 
encodes a 25- to 27-kda protein believed to negatively regulate HIV replication 
and expression (Ahmad and Venkatesan, 1988; Luciw et al., 1987). Cloned HIV 
proviruses designed to contain mutations or deletions in the nef gene have been 
shown to give rise to viruses which replicate to higher titers in tissue culture than 
the wild-type virus (Luciw et al., 1987). Moreover, the nef gene product has been 
proposed to downregulate HIV-1 transcription by activating tram-acting factors 
which in turn interact with the negative regulatory element (NRE) in the 
upstream U3 region of the 5’-LTR (Ahmad and Venkatesan, 1988).
Figure 7 presents a summary of the regulatory functions of the HIV trans- 
activators. The cis-acting sequences in the viral genome (TAR and crs) inhibit or 
downregulate viral gene expression, allowing only low levels of double-spliced 
viral transcripts to be synthesized early after infection. As the gene products of tat 
and rev continue to accumulate, a threshold of these positive /ram-activators is 
reached, after which they greatly increase the expression of TAR-containing RNA 
and incompletely spliced viral transcripts, respectively. In the meantime,
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Figure 7. The HIV fra/u-activators. tat, rev, and nef are translated from double­
spliced viral mRNA, denoted as "early transcripts", containing coding sequences 
flanking the env gene. Transcription initiates from the 5’-LTR. (a) tat acts upon 
TAR, which is present just 3’ to the initiation site of trancription and which 
becomes a part of the 5’-terminal sequences in HTV full-length RNA, to result in 
large increases in TAR-containing RNA species, (b) rev acts on car (cw-acting 
anti-repression sequence) to increase the expression of full-length and single­
spliced HIV RNA, denoted as "late transcripts". In the absence of rev, double­
spliced "early transcripts" predominate. Full-length and single-spliced viral RNA 
are quickly processed or degraded since they contain crs elements (ds-acting 
repression sequence) in gag and env coding regions, (c) nef is encoded by an ORF 
located 3’ to the env gene and negatively regulates viral gene expression, either by 
decreasing cellular signaling, or by acting on the negative regulatory element 
(NRE) in the upstream U3 region of the 5’-LTR. The open boxes at the 3’-end of 
viral transcripts represent U3 and R sequences. (From Peterlin and Luciw, 1988).
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accumulated levels of nef decrease cellular signaling and viral transcription. The 
balance between the function of these viral regulators and their effects within the 
infected cell is never completely achieved, and as a result, the infected cell dies 
while enough virions infect other cells to insure survival of the virus (Franza et 
al., 1988; Peterlin et al., 1988; Peterlin and Luciw, 1989).
Much less is known about the function of the other small genes of 
HIV-1 and -2. vif, previously known as sor, orfA, P \ or Q, encodes a 23-kda 
protein (Lee et al., 1986; Kan et al., 1986). Because cloned proviral genomes 
containing mutations in the vif gene yield low levels of infectious viral particles, 
the vif gene product has been suggested to be required for viral infectivity 
(Sodroski et al., 1986; Strebel et al., 1987). Precise functions for vpr, vpu, and vpx 
have yet to be defined.
Much has been learned in the past five years in understanding the 
molecular biology of lentiviruses. Relative to HIV-1, however, progress in 
discovering the patterns of gene expression of other lentiviruses has been lagging 
behind. In the case of visna virus, a triple-spliced viral mRNA, whose four exons 
contain sequences from the 5’-end of the viral genome, the 3’-end of pol, a short 
ORF immediately upstream of env (S), and sequences at the 3’-end of env, 
respectively, has been shown to encode viral /rani-activating functions (Mazarin et 
al., 1988; Davis and Clements, 1989). A similar double-spliced viral mRNA, 
whose three exons contain sequences from the 5’-end of the viral genome, SI, and 
S3 ORFS of EIAV (Figure 6) has been reported to code for an EIAV trans- 
activator (Derse et al., 1989). It is believed that by dissecting the functions of the
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structural and regulatoiy genes of lentiviruses in general, and the HIV’s in 
particular, measures can then be taken to interfere or block the action of such 
genes and their encoded products, thus providing therapeutic or preventative 
protocols against lentivirus-induced diseases, including AIDS.
The patterns of transcription of lentiviruses in infected cells have proven to 
be quite complex, involving multiple splicing events required for the generation of 
virus-encoded regulatory frans-acting proteins which, in turn, act on cu-acting 
sequences on the viral genome to enhance viral transcription or influence the 
ratio of spliced to unspliced RNA’s. The objectives of the current study have been 
to answer some of the unanswered, yet fundamental, questions on the molecular 
biology of equine infectious anemia virus (EIAV).
RESEARCH OBJECTIVES
The main objective of the body of research presented here has been to 
characterize the transcriptional properties of EIAV in virus-infected cells. 
Questions regarding different aspects of this objective are listed below, along with 
their significance.
(1) How many virus-specific transcripts are encoded by EIAV in virus- 
infected cells? What are the relative levels, sizes, and kinetics of synthesis of 
EIAV-specific transcripts? Moreover, are there any differences in patterns of 
EIAV transcription when comparing persistent to cytopathic EIAV infections? 
Answers to these questions are necessary in order to carefully examine the 
genetic properties of EIAV and the possibility of differential expression of the 
viral genome during persistent and cytopathic infections.
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(2) What are the splicing patterns utilized in generation of the spliced 
EIAV mRNA’s in infected cells? Can the location of the splice donor and 
acceptor sites used for generating the spliced viral mRNA’s be mapped on the 
viral genome? Characterization of the viral mRNA splicing patterns is a 
prerequisite to defining the exact nucleotide sequence of these mRNA’s, which in 
turn is required for analysis of the potential of these mRNA’s to encode viral 
structural, replicative, and regulatory proteins.
(3) Do the short ORFs on the EIAV genome code for any proteins, such 
as the fra/w-acting proteins encoded by HIV-1 or visna virus, and if so what are 
the transcriptional and translational mechanisms used for their synthesis? To 
better understand the molecular biology of lentiviruses it is important to search 
for these regulatory proteins and to understand their function.
(4) Finally, the unique nature of the persistent disease induced by EIAV, 
in which the infected horse eventually brings the disease under control, provides 
an exciting venue for answering some of the complex questions on the biology of 
other important lentiviruses such as HIV-1. Do the determined patterns of EIAV 
gene expression correlate with the complex patterns observed in other lentivirus 
systems or are they in any way different or unique? Such information is vital to 
understanding patterns of lentiviral gene expression and designing diagnostic, 
therapeutic, and preventative measures for combating lentiviral diseases.
The first objective has been accomplished by analysis of RNA from EIAV- 
infected cells in Northern blot hybridizations using a battery of subcloned, gene- 
specific proviral DNA probes obtained from the cloned EIAV provirus. The
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splicing patterns of EIAV, outlined in objective (2), have been analyzed by 
cloning and sequencing of cDNA obtained from poly(A)+ RNA of EIAV-infected 
cells, by Northern hybridization analysis using short oligonucleotide DNA probes 
complementary to sequences upstream of putative splice donor sites near the 5’- 
end of the EIAV gag gene, and also by S 1-nuclease mapping studies of RNA 
from virus-infected cells. Characterization of splicing patterns and mapping of 
splice donor and acceptor sites on the viral genome has facilitated the 
determination of coding sequences within the spliced EIAV mRNA’s, which in 
turn has allowed the design of experimental approaches for addressing objective
(3). Subcloning of specific EIAV cDNA fragments encoding these mRNA’s into 
plasmid vectors for in vitro transcription/translation or expression in eukaryotic 
cells has provided a means for preliminary analysis of the expressed protein 
products. Future detailed characterization of the expressed proteins, including an 
analysis of their reactivity with appropriate antisera, would then allow their 
assignment to specific EIAV genes.
CHAPTER 2
MATERIALS AND METHODS
Cell cultures and virus strains
Primary cultures of fetal equine kidney (FEK) and fetal donkey dermal 
(FDD) cells were prepared and maintained as described previously (Orrego et al., 
1982). A prototype stock of EIAV, obtained by propagation of the Wyoming cell- 
adapted strain of EIAV (Malmquist et al., 1973) in FEK cells, was used to carry 
out infection of confluent monolayers of FEK cells at a multiplicity of infection of
1.0. In addition, an FDD-adapted stock of EIAV, prepared by propagation of 
prototype EIAV in FDD cells, was used to infect confluent monolayers of FDD 
cells at a multiplicity of infection of 1.0.
Isolation and purification of total and poly(A)+-selected cellular RNA
To inactivate contaminating RNases, all solutions used for preparation of 
RNA were prepared using diethylpyrocarbonate (DEPC)-treated double-distilled 
water (ddH20). In addition, all solutions were subjected to a second round of 
DEPC treatment following their preparation, with the exception of Tris buffers. 
For DEPC treatment, 2 ml of DEPC was added to 100 ml of water or solution 
and shaken vigorously. After an overnight incubation at room temperature, the 
solution was autoclaved to remove remaining traces of DEPC. In addition, all 
glassware used for preparation of such solutions wws sterilized by baking at 
200°C for 8 hours.
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Total cellular RNA was isolated from EIAV-infected or uninfected cells by 
a modified guanidinium thiocyanate extraction method (Chirgwin et al. 1979, 
Maniatis et al., 1982). Briefly, using repeated washes with phosphate buffered 
saline (PBS) containing 4mM EDTA (pH 7.0), infected FEK cells were harvested 
from roller bottles at 3-4 weeks post-infection, and infected FDD cells were 
recovered from flasks at the peak of the cytopathic effect (10-12 days after 
infection with FDD-adapted EIAV). The cells were pelleted in 50 ml 
polypropylene conical centrifuge tubes at 2,000 rpm for five minutes using an IEC 
HN-SII table-top clinical centrifuge, and immediately resuspended in 5-10 ml of 
guanidinium thiocyanate lysis buffer [4.0 M guanidinium thiocyanate, 0.5% 
sodium-N-lauroyl sarcosine, 5.0 mM sodium citrate (pH 7.0), 0.1 M 2-mercapto- 
ethanol]. The cells were lysed by repeated passage through a 23-gauge needle, 
which also resulted in shearing of the chromosomal DNA Four grams of solid 
CsCl was dissolved in each 10.0 ml of homogenate (0.4 g/ml final) and the 
homogenate was gently layered over a 3.25 ml cushion of sterile 5.7 M CsCl in 
sterilized 13.5 ml Sarstedt polyallomer ultracentrifugation tubes. Following 
ultracentrifugation for 18 hours at 28,500 rpm at 20°C in a Beckman SW40Ti 
rotor, the cellular homogenate and the CsCl cushion were carefully aspirated out 
and the inside walls of the tube were wiped dry by a sterile gauze. The light 
brown pellet of RNA was resuspended in 300 ul of 10.0 mM Tris.Cl (pH 7.5), 5.0 
mM EDTA (pH 7.0), 1.0% SDS, and extracted twice with phenokchloroform: 
isoamyl alcohol (25:24:1). The aqueous supernatant was brought up to 0.3 M in 
sodium acetate (pH 5.2) and precipitated by addition of three volumes of ethanol.
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Poly(A)+ RNA was purified by two cycles of oligo(dT)-cellulose chromatography 
of total cellular RNA (Maniatis et al., 1982), or by direct oligo(dT)-cellulose 
chromatography of cellular lysates using the Fast Track mRNA Isolation Kit from 
Invitrogen, according to the manufacturer’s protocol.
For time-course studies on EIAV RNA synthesis, various time-points after 
infection were used for recovery of infected FEK and FDD cells, as described in 
Chapter 3.
Subcloning of EIAV proviral DNA fragments
EIAV proviral DNA fragments were obtained by restriction enzyme 
digestions of an EIAV proviral DNA clone, lambda 12 (Derse et al., 1987; 
Rushlow et al., 1986; Stephens et al., 1986). Restriction digestions were performed 
according to standard protocols (Maniatis et al., 1982) using the 10X digestion 
buffer provided by the enzyme’s manufacturer and under the manufacturer’s 
recommended reaction conditions. Typically, 5 to 10 ug of DNA was digested by 
10 to 20 units of enzyme for at least 5 hours at the appropriate reaction 
temperature. Restriction fragments of EIAV proviral DNA were subjected to 
electrophoresis through 0.8-1.2% low melting-point agarose, normal agarose, or 
6.0-8.0% polyacrylamide gels (Maniatis et al., 1982), following which the gels were 
stained with 0.5 ug/ml ethidium bromide for visualization of the DNA bands by 
UV illumination. After excision of appropriate DNA bands from gels, DNA was 
purified by chromatography through a column of NACS-52 resin (BRL) or by the 
use of a GeneClean Kit (Bio 101). Purified viral DNA fragments were typically 
ligated to appropriately linearized plasmid vectors at a molar ratio of 20:1
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insert:vector under standard ligation reaction conditions (Maniatis et al., 1982). 
Aliquots of the ligatation reactions were used to transform competent E. coli 
JM101 or DH5a cells to antibiotic resistance (Hanahan, 1985). Recombinant 
clones were identified by restriction enzyme mapping of minilysate plasmid DNA 
prepared from 2 ml overnight cultures of antibiotic resistant clones by the 
alkaline lysis method (Bimboim and Doly, 1979; Maniatis et al., 1982). 
Recombinant plasmids were then prepared on a large scale from 2 liter cultures 
of appropriate clones and purified by two cycles of equilibrium density 
ultracentrifugation through CsCl-ethidium bromide gradients (Maniatis et al., 
1982).
Labeling of probes for Northern hybridization analysis
Recombinant plasmids containing subcloned EIAV proviral DNA 
fragments, which were to be used as probes for Northern hybridizations, were 
digested with appropriate restriction enzymes, and the EIAV-specific insert DNA 
fragments were purified following gel electrophoresis as described above. 50 to 
100 ng of each fragment was then labeled with [a-32P]dCTP using a random 
primer labeling kit from BRL (Feinberg and Vogelstein, 1983). Oligonucleotide 
probes (see below) were prepared by 5’-end labeling of 200 ng of each 
oligonucleotide with [y-32P]ATP and polynucleotide kinase (Maniatis et al., 1982). 
Unincorporated 32P-labeled ribo- or deoxyribonucleotides were removed from the 
labeling reactions by chromatography through Sephadex G-50 spun columns, as 
described (Maniatis et al., 1982). Typically, specific activities greater than 5X10®
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cpm/ug for restriction DNA fragments and about 1X109 cpm/ug for oligo­
nucleotides were obtained.
Northern, Southern, and colony hybridization analyses
For Northern hybridization analysis, 2.5 ug of poly (A)+ RNA or 15.0 ug 
of total RNA from infected or uninfected cells was subjected to electrophoresis in 
20X20 cm 1.0% or 1.4% agarose-formaldehyde gels in 50 mM MOPS (pH 7.0), 1 
mM EDTA buffer (Gerard and Miller, 1986). Electrophoresis was carried out at 
100 volts for 1 hour without buffer circulation and at 30 volts for 14 hours with 
buffer circulation. To check for the integrity of RNA samples, the gels were 
stained by soaking in a 5.0 ug/ml solution of ethidium bromide in water for 5 
minutes in the dark and destained for 3 to 8 hours in water in the dark. The 
stained RNA bands were then visualized by short-wave UV illumination of the 
gel. For transfer of RNA the staining step was omitted, and the gel was washed 
immediately following electrophoresis for 1 hour in 10X SSC (IX SSC is 0.15 M 
NaCl, 0.015 M sodium citrate) to remove the formaldehyde. The gel was then 
transferred overnight to GeneScreen or GeneScreenPlus nylon membranes (New 
England Nuclear-DuPont) in 10X SSC using the capillary Southern transfer 
method (Maniatis et al., 1982). Following the transfer, the membrane was baked 
for 2 hours at 80°C in a vacuum oven and prehybridized at 42°C for 2-4 hours in 
a buffer containing 50% formamide, 5X Denhardt (Maniatis et al., 1982), 6X 
SSC, 1% SDS, 250 ug/ml denatured salmon sperm DNA and 25 mM sodium 
phosphate (pH 6.5). Hybridization was carried out at 42°C for 18-24 hours using 
1X106 cpm of 32P-labeled probe per ml of hybridization solution, which contained
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the same composition as the prehybridization buffer except that IX Denhardt was 
used. Following hybridization, the membranes were washed for 30 minutes at 
room temperature in 2X SSC, 0.2% SDS, and for 30 minutes at 65°C in 0.2X 
SSC, 0.2% SDS. The membranes were then subjected to autoradiography at 
-70°C for 12-36 hours.
For Southern hybridization analysis, DNA fragments were fractionated by 
electrophoresis through 1.0% agarose gels. Denaturation, neutralization, and 
transfer from the gel onto a nitrocellulose membrane was performed according to 
standard protocols (Maniatis et al., 1982). Baking, prehybridization, hybridization, 
and autoradiography was exactly as described for Northern hybridizations above.
For colony hybridization analysis, individual E. coli colonies were picked by 
sterile toothpicks and streaked as short lines (2-3 mm long) on sterile circular 
nitrocellulose membranes placed on LB agar plates containing the appropriate 
antibiotic. A grid pattern taped to the back of the plate was used to identify the 
location of individual colonies on the membrane. The plate was inverted and 
incubated at 37°C until colonies had grown to 0.5-1.0 mm in width (6-8 hours). 
Lysis of the bacterial colonies on the membrane were performed as described 
(Maniatis et al., 1982). Baking, prehybridization, hybridization, and 
autoradiography of the membrane was exactly as described for Northern 
hybridizations above.
Chemical synthesis and purification of oligonucleotides
The four oligonucleotides used in this study were the generous gift of Dr. 
K. E. Rushlow, Battelle Memorial Institute, Columbus, Ohio. The first
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oligonucleotide, used to prime first-strand cDNA synthesis, was a 30-mer and had 
the following sequence:
5’-ACTGAAGTAATTTTGAAATGGTCrACACCC-3’
The sequence of the oligonucleotide is complementary to a 30 nucleotide-long 
sequence immediately downstream of the Smal site within the EIAV env gene 
(positions 1642-1672 of Rushlow et al., 1986; Figure 11 A). The other three 
oligonucleotides (SD-1, SD-2, and SD-3) were used as probes in Northern 
hybridization analyses and their primary sequence is shown in Figure 13.
The oligonucleotides were synthesized on an Applied Biosystems 380A 
DNA Synthesizer. Following synthesis, the deprotected oligonucleotides were 
purified by chromatography through oligonucleotide purification cartridges 
(Applied Biosystems) according to the manufacturer’s protocol. 
cDNA synthesis and cloning
Double-stranded cDNA was synthesized from 13.0 ug of poly(A)+ RNA 
obtained from EIAV-infected FDD cells, using a cDNA Synthesis Kit from BRL. 
The manufacturer’s protocol was exactly followed, except that 3.0 ug of the 
synthetic 30-mer oligonucleotide described above was used to prime first-strand 
cDNA synthesis instead of the oligo(dT) primer provided in the kit. Following the 
synthesis of second-strand cDNA the double-stranded cDNA products were 
precipitated with ethanol.
For cloning of cDNA the double-stranded cDNA products were tailed 
with oligo(dC) and annealed to oligo(dG)-tailed, PstI digested pUC9 DNA. 
Following this strategy a PstI site is created at the 5’- and 3’-ends of the cloned
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cDNA. The ethanol precipitated cDNA products were pelleted, dried, and 
resuspended in 10 ul sterile ddH20 . The oligo(dC)-tailing reaction was set up by 
addition of 5 ul of 10 mM dCTP (1 mM final concentration) and 10 ul of the 
BRL 5X tailing buffer (IX final concentration) to the double-stranded cDNA.
The volume of the mixture was brought up to 48.5 ul with sterile ddH20 , after 
which the contents were mixed and the mixture was incubated in a 37°C water 
bath for 5 minutes. The tailing reaction was initiated by addition of 20 units (1.5 
ul) of BRL Terminal Deoxynucleotidyl Transferase (50 ul final reaction volume) 
and the mixture was incubated at 37°C. Five ul aliquots were removed from the 
reaction at 30 second intervals (10 aliquots), and to inactivate the enzyme each 
aliquot was transferred to individual microfuge tubes pre-incubated in a 70°C 
water bath for 10 minutes. The 20 ul annealing reaction for each aliquot was set 
up by addition of 2 ul of 10X annealing buffer [100 mM Tris.Cl (pH 7.5), 1,000 
mM NaCl, 1 mM EDTA (pH 7.5)], 11 ul of sterile ddHzO, and 2 ul of 11 ng/ul 
oligo(dG)-tailed, PstI digested pUC9 (Pharmacia). Annealing was carried out at 
58°C for 3 hours. After a brief centrifugation step for collection of residual water 
on the inside walls of the tubes, the annealing reaction was continued by 
incubation at room temperature overnight.
A 5 ul aliquot from each 20 ul annealing reaction was used to transform 
BRL library efficiency competent DH5a E. coli cells (Hanahan, 1985). 
Transformants were plated on LB plates (Maniatis et al.) containing 100 ug/ml 
ampicillin, 80 ug/ml X-gal, and 10 ug/ml IPTG. Plates were incubated for 12
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hours at 37°C, and colonies exhibiting the white phenotype were randomly picked 
for colony hybridization analysis, as described above.
Nucleotide sequencing
Double-stranded DNA fragments to be sequenced were isolated and 
purified on 1.0-1.2% agarose gels, as described above, and subcloned into the 
replicating form (RF) DNA of M13mpl8 or M13mpl9 vectors. Single-stranded 
DNA from the M13 phage particles was sequenced by the dideoxy chain 
termination method (Sanger et al., 1977), following which the sequencing reaction 
mixtures were subjected to electrophoresis on 10% polyacrylamide-8% urea 
sequencing gels (BRL).
SI nuclease mapping
The four probes used for SI nuclease mapping of RNA from ELAV- 
infected and uninfected FDD cells are described in detail in Chapter 3 and 
schematically diagrammed in Figure 16. To create the M13 "tag" sequence at the 
intronic end of probe pi, a 308-bp Taql-PvuU EIAV proviral DNA restriction 
fragment was subcloned into M13mpl8 RF DNA digested with Accl and Smal. 
The cloned DNA was then excised out as a 550-bp Narl fragment containing a 
300-bp Narl-PvuVL proviral DNA fragment and a 250-bp M13mpl8 Smal-Narl tag 
attached from its Smal end to the PvuU site (Figure 16B).
Similarly, probe p2 was constructed by cloning a 450-bp Ncol-BamHl EIAV 
proviral DNA restriction fragment, which had been previously blunt-ended at the 
Ncol site by treatment with T4 DNA polymerase (Maniatis et al., 1982), into 
M13mpl9 RF DNA digested with BamUl and Smal. The cloned DNA was then
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excised out as a 611-bp BamHL-BgM containing a 450-bp BamHL-Ncol proviral 
DNA fragment and a 161-bp M13mpl9 Smal-BglU tag attached from its Smal 
end to the blunt-ended Ncol site (Figure 16C).
Probes p3 and p4 did not contain any tag sequences and were directly used 
as 617-bp PvuU-Hindm and 385-bp Dral-Scal proviral DNA restriction fragments.
Probe p i was prepared by labeling the 550-bp Narl fragment at its 3’-ends 
in a fill-in reaction with [a-32P]-dCIP and the Klenow fragment of E. coli DNA 
polymerase I (Maniatis et al., 1982). Probe p2 was prepared by treatment of the 
611-bp BamYR-BgUl fragment with calf intestinal phosphatase (Maniatis et al., 
1982), and labeling of the dephosphorylated 5’-ends with [y-32P]ATP and 
polynucleotide kinase (Maniatis et al., 1982). Probe p3 was prepared by labeling 
the 617-bp PvuU-Hindlll fragment at its 3’-ends with [a-32P]dATP and 
[a-32P]dCTP by replacement synthesis with T4 DNA polymerase (O’Farrell, 1981). 
Finally, probe p4 was prepared by treatment of the 385-bp Dral-Scal fragment 
with calf intestinal phosphatase (Maniatis et al., 1982), and labeling of the 
dephosphorylated 5’-ends with [y-32P]ATP and polynucleotide kinase (Maniatis et 
al., 1982).
For SI nuclease mapping, a modification of procedures by Nash et al. 
(1984) and Ausubel et al. (1987) was used. About 1X106 Cerenkov counts of each 
probe were added to 40 ug of total cellular RNA from ELAV-infected or 
uninfected FDD cells, and the mixture was precipitated with ethanol. The 
precipitate was pelleted, washed with 70% ethanol-30% DEPC-treated ddH20 , 
and air-dried. The pellets were thoroughly dissolved in 30ul of SI hybridization
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buffer [80% deionized formamide, 40 mM PIPES (pH 6.4), 400 mM NaCl, 1 mM 
EDTA (pH 8.0)], and the resuspended RNA-probe mixture was immersed in an 
85°C water bath for 15 minutes. The hybridization mixture was then immediately 
transferred to water baths adjusted to 50°C (in the case of probes p i and p3) or 
55°C (in the case of probes p2 and p4) and incubated overnight. The following 
mix was then added to the hybridization reaction: 150 ul 2X SI nuclease buffer 
[0.56 M NaCl, 0.1 M NaOAc (pH 4.5), 9 mM ZnS04], 3 ul 2.0 mg/ml single­
stranded calf thymus DNA, 147 ul DEPC-treated ddH20 , and 300 units SI 
nuclease (BRL). The contents were mixed and incubated at 30°C for 60 minutes, 
after which the SI digestion was stopped by addition of 80 ul of SI stop buffer 
[4.0 M ammonium acetate, 20 mM EDTA (pH 8.0), 40 ug/ml yeast tRNA]. The 
digest was extracted twice with phenol:chloroform:isoamyl alcohol (25:24:1), and 
the aqueous supernatant was precipitated with ethanol. To remove traces of salt, 
the ethanol precipitated samples were pelleted, resuspended in sterile ddH20 , 
and the ethanol precipitation was repeated two more times. The final pellet was 
washed with 70% ethanol, dried in a Speedvac evaporator, and resuspended in 3 
ul of TE buffer (Maniatis et al., 1982). Four ul of formamide loading dye [95% 
deionized formamide, 20 mM EDTA (pH 7.5), 0.05% bromophenol blue, 0.05% 
xylene cyanol] was added, the sample was boiled for 4 minutes, and quenched 
immediately on ice. The entire sample was then subjected to electrophoresis 
through a 6.0% polyacrylamide-8.0 M urea sequencing gel. Electrophoresis was 
typically stopped just as the bromophenol blue reached the bottom of the gel.
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Mspl-digested pBR322 DNA, labeled with [a-32P]dCTP by filling-in with Klenow 
(Maniatis et al., 1982), was run in parallel lanes as size marker.
In vitro transcription and translation
Construction of the pSP65 plasmid containing the 2980-bp BamHl-Pstl S2- 
env cDNA insert is diagrammed in Figure 19. Briefly, a ligation reaction 
containing the 270-bp Smal-BamHL splice-junction cDNA, a 2710-bp BamHl-Pstl 
cDNA fragment from a separate cDNA clone (#3006), and pUC19 DNA digested 
with Smal and PstI was carried out [The PstI end of the second cDNA fragment 
had been originally created through cloning of that cDNA into pUC9 by 
oligo(dC)-(dG) tailing]. As a result, a 2980-bp Smal-Pstl hybrid cDNA insert was 
cloned into pUC19. Appropriate recombinants were identified by restriction 
enzyme mapping and the 2980-bp insert was excised out of pUC19 by digestions 
with Sacl and PstI. The 2980-bp Sacl-PstI fragment was then cloned into pSP65 
DNA which had been digested by Sacl and PstI. Appropriate recombinants were 
again identified by restriction enzyme mapping.
To prepare templates for in vitro transcription, the pSP65 plasmid 
containing the 2980-bp Sad-Pstl cDNA insert was then linearized by either 
HindUl or Mlul (Figure 19). Capped transcripts were synthesized in 50 ul 
reactions, containing the cap analog GpppG (Pharmacia), using an in vitro 
transcription kit (Promega Biotec) and according to the manufacturer’s protocol, 
based on previously published procedures (Krieg and Melton, 1984). In vitro 
translation reactions of the synthetic transcripts were performed in wheat germ 
extracts in the presence of 35S-methionine, as described previously (Bartlett et al.,
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1982). Incorporation of 35S-methionine was determined by assaying an aliquot of 
the translation reaction for acid-insoluble radioactivity using Whatman 3mm filter 
paper discs.
Construction of the p9SR426 expression plasmid, transfections, and indirect 
immunofluorescence assays
A 426-bp Sspl-Smal restriction fragment of the EIAV proviral DNA, 
containing the entire S2 coding sequence and the the first 379 nucleotides of the 
env gene, was cloned into the p91023(B) expression vector (Figure 21). In 
addition to its unique EcoRI cloning site, the p91023(B) vector also contains a 
unique BglU cloning site immediately upstream of the FcoRI site. The 426-bp 
Sspl-Smal fragment was initially cloned into the Smal site of plasmid TrpSF9, 
and the orientation of the insert in the recombinant clones was identified by 
restriction enzyme mapping. The insert DNA was then excised as a Bglll-EcoRl 
fragment and ligated to p91023(B) DNA digested with BglII and EcoRl. The 
recombinant plasmid, termed p9SR426, was then grown on a large scale and 
subjected to two cycles of equilibrium density ultracentrifugation through CsCl- 
ethidium bromide gradients (Maniatis et al., 1982). COS-7 cells were grown on 
sterile tissue culture chamber slides to about 50% confluency. Five ug of the 
plasmid was transfected onto COS-7 cells as a calcium phosphate co-precipitate 
followed by a 15% glycerol shock, as described previously (Fordis and Howard, 
1987). Indirect immunofluorescence assays were performed at 48 hours post- 
transfection, using monoclonal antibody #86 or rabbit polyclonal S2b antibody, 
according to previously published procedures (Pereira et al., 1980).
CHAPTER 3 
RESULTS
I. IDENTIFICATION OF EIAV-SPECIFIC TRANSCRIPTS IN INFECTED 
CELLS
The cell-adapted Wyoming (prototype) strain of EIAV establishes a 
persistent infection in fetal equine kidney (FEK) cells grown in tissue-culture, 
leading to continuous virus production for up to 4-5 weeks after the initial 
infection, during which no cytopathic effects are exerted by the replicating virus 
on the infected cells. Infection of fetal donkey dermal (FDD) cells by FDD- 
adapted EIAV, a strain of the virus obtained by propagation of prototype EIAV 
in FDD cells, however, results in a distinct and observable cytopathic effect 
characterized by rounding and detachment of infected cells at 10-12 days post­
infection.
By comparison to other retroviruses, transcription of the EIAV provirus 
initiates at the 5’-terminus of the R region in the 5’-LTR. Since the R-U5-leader 
sequences are present in both full-length genomic and spliced viral mRNA’s, a 
proviral DNA fragment containing nucleotide sequences from the R-U5 region of 
the LTR would share sequence homology with the 5’-ends of all viral mRNA’s. 
Such a DNA fragment, hereafter referred to as the "5’-LTR probe", should 
hybridize to all virus-specific transcripts and once radiolabeled can be used as a 
general probe for detection of all viral mRNA’s actively transcribed in infected 
cells.
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A 226-bp restriction fragment of the EIAV provirus, beginning at 50 
nucleotides upstream of the R region in the 5’-LTR (within the U3 sequences) 
and extending 63 nucleotides downstream of the U5 region, was radiolabeled with 
32P and used as the 5’-LTR probe in Northern blot hybridization analysis of 
EIAV-specific transcripts during persistent and cytopathic infection of FEK and 
FDD cells, respectively. Total cellular RNA was isolated from FEK cells at three 
weeks after infection with prototype EIAV, from FDD cells at the peak of 
cytopathic effects at twelve days after infection with FDD-adapted EIAV, and 
from uninfected FEK and FDD cells as negative controls. Fifteen micrograms of 
total RNA from each source was subjected to electrophoresis in a 1.0% 
denaturing agarose-formaldehyde gel, transferred to the hybridization membrane, 
and hybridized with the 5’-LTR probe. The left panel in Figure 8 shows the 
ethidium bromide-stained agarose-formaldehyde gel of total RNA samples, while 
an autoradiogram of the Northern blot of the same gel hybridized to the 5’-LTR 
probe is presented in the right panel of Figure 8. In both infected cell-lines, two 
major species of hybridizing EIAV-specific transcripts are detected: an 8.2-kb 
genome-length RNA and a 3.5-kb RNA. Also detected in RNA from both 
infected cell lines is a low abundance 1.5-kb RNA species which migrates just 
below the 18S rRNA band on the gel. No EIAV-specific transcripts are detected 
in RNA from uninfected cells, indicating that there is no endogenous expression 
of ELAV-related RNA in these cells and that the hybridizing RNA species 
present in RNA from infected cells are a result of EIAV infection.
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Figure 8. Northern hybridization analysis of total RNA from EIAV-infected and 
uninfected FEK or FDD cells. Left. 1.0% Agarose-formaldehyde gel of total 
cellular RNA from FEK cells infected with prototype EIAV (lane 1), FDD cells 
infected with FDD-adapted EIAV (lane 2), uninfected FEK cells (lane 3), and 
uninfected FDD cells (lane 4). Lane M contains molecular weight markers (0.3- 
to 9.5-kb RNA ladder of BRL) whose mobilities are indicated on the left. Right. 
Northern blot of the gel on the left panel, hybridized to the 226-bp Mlul-BamHl 
5’-LTR probe. The position of 28S and 18S rRNA bands on both the gel and the 
blot are indicated. The numbers on the right corespond to the molecular weight 
values for the three observed species of EIAV mRNA’s.
2 8 s
18 s
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Densitometric analysis of the Northern blot in Figure 8 reveals that there 
is almost a 10-fold higher level of viral RNA’s in infected FDD cells at the peak 
of the cytopathic effect relative to that in persistently infected FEK cells. In 
addition, the results indicate that the 8.2- and 3.5-kb RNA are present at nearly 
equal concentrations in infected FEK cells, while the concentration of the 3.5-kb 
RNA is about three-fold greater than that of the full-length transcript.
Immunofluorescence studies have shown the EIAV infection of FDD cells 
to be asynchronous, resulting in infected cells comprising about 30% of the total 
cell population, while during infection of FEK cells nearly 100% of the cell 
population is infected by the virus (Issel and Montelaro, unpublished data). 
Taking into account the asynchronous nature of viral infection in FDD cells, it 
appears that the levels of EIAV-specific RNA’s are nearly 30-fold higher during 
the cytopathic infection of FDD cells relative to the persistent infection of FEK 
cells. Moreover, the relatively high levels of the 3.5-kb mRNA in infected FDD 
cells suggests enhanced levels of 8.2-kb genome-length viral RNA splicing during 
this cytopathic EIAV infection.
The presence of abundant quantities of 28S and 18S rRNA in samples of 
total cellular RNA, as clearly seen in Figure 8A, introduces inherent problems in 
identification of specific RNA’s present on a hybridization membrane which share 
sequence homology with the hybridization probe. In the absence of the rRNA 
species, the probe would hybridize to a background "smear" of degraded 
homologous RNA on the membrane, in addition to the specific non-degraded 
RNA species. However, when the abundant non-hybridizing rRNA species are
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present on the membrane, they physically block the hybridization of the probe to 
the background smear of degraded homologous RNA at the position of each 
rRNA species on the membrane, resulting in the re-appearance of the 
background immediately below the lower boundary of each rRNA which then 
appears as a faint hybridizing band on the Northern blot. This band is present 
just below the position of 28S and 18S rRNA in Figure 8B, and has been 
observed in repeated experiments involving Northern hybridization of total RNA 
samples.
To clarify this inherent problem and also to better detect any EIAV- 
specific low molecular transcripts which migrate slightly faster than 18S rRNA 
during denaturing gel electrophoresis, poly(A)+ RNA, which contains little or no 
rRNA, was isolated and purified from uninfected and EIAV-infected FDD cells 
and used as substrate for Northern hybridization analysis. Furthermore, to identify 
the gene-specific content of the EIAV-specific mRNA’s in infected cells, a battery 
of subgenomic EIAV DNA fragments (Table II), in addition to the 5’-LTR 226- 
bp fragment, were used as probes in Northern hybridization analyses. Using 
unique restriction sites on the EIAV proviral DNA, the DNA fragments were 
individually subcloned so that each, with the exception of the 5’-LTR probe, 
represents sequences from each of the seven genes (including the short ORF’s) of 
EIAV. By designing the gene-specific probes spanning across the EIAV genome, 
separate Northern hybridizations were carried out using each individual probe, 
and the identity of viral mRNA’s containing sequences complementary to each 
viral gene were identified. Figure 9 shows a composite of the location of the
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Table II. Panel of EIAV proviral DNA restriction fragments used as probes in Northern 
hybridization analyses.
Probe Restriction Fragment Specificity within the 
EIAV genome
EIAV mRNA Specificity
A 226-bp Mlul-Barnm 5’ - LTR All mRNA’s
B 393-bp PvuU-Kpril gag Full-length
C 511-bp Smal-Sstl pol Full-length
D 102-bp Pvull-Sspl SI Full-length, S I , env*
E 114-bp £amHI-7a<7l S2 Full-length, S2, env
F 417-bp Sphl-Xbal env Full-length, env
G 320-bp Avail S3 Full-length, env, S3
* The hybridization of this probe to the env mRNA would be dependent on the env splice 
acceptor site being located upstream of the SspI site.
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Figure 9. Northern hybridization analysis of EIAV-specific poly(A)+ RNA’s in 
FDD cells infected with FDD-adapted EIAV. A diagram of the EIAV proviral 
DNA genome and the location of the six open reading frames is represented on 
top of the figure. Based on DNA sequence data (Rushlow et al., 1986; Stephens et 
al., 1986) solid triangles represent the location of consensus splice donor sites and 
open triangles represent the location of consensus splice acceptor sites. The 
stippled bars, labeled A through G, show the location and size of the subgenomic 
probes relative to the EIAV genome. The bottom portion of the figure shows the 
results of hybridization of 2.5-ug of poly(A)+ RNA from FDD cells infected with 
FDD-adapted EIAV, isolated at the peak of the cytopathic effect, to each of the 
subgenomic probes A-G. Panel H, RNA from uninfected FDD cells. The 
positions of the 8.2-, 3.5-, and 1.5-kb viral mRNA’s are indicated. Panel Al 
represents a Northern blot of a 1.5% agarose-formaldehyde gel, while the 
remaining panels, including A2, are blots of a 1.0% gel. The molecular weight 
markers used in this experiment were the 0.3- to 9.5-kb RNA Ladder (BRL).
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various probes on the EIAV genome and their pattern of hybridization to 
Northern blots of poly(A)+ RNA from FDD cells infected with FDD-adapted 
EIAV. As shown in Figure 9, panels A l and A2, three species of viral RNA were 
identified in poly(A)+ RNA of infected FDD cells following hybridization to the 
5’-LTR probe: an 8.2-kb genome-length mRNA, a 3.5-kb mRNA, and a low- 
abundance 1.5-kb mRNA. Panel A l is a Northern blot of a 1.4% agarose- 
formaldehyde gel, with the higher percentage gel resulting in a sharpened 1.5-kb 
hybridizing RNA band, while panel A2 is a blot of a 1.0% agarose-formaldehyde 
gel. As demonstrated before, no viral-specific RNA species were detected in RNA 
from uninfected cells (Figure 9, panel H).
Northern blots of poly(A)+ RNA from infected FDD cells, run on a 1.0% 
agarose-formaldehyde gel, were also hybridized to a panel of probes spanning the 
EIAV genome (probes B through G). As shown in Figure 9, the gag- and the pol- 
specific probes (B and C) hybridize only to the full-length 8.2-kb viral mRNA, 
indicating that this transcript represents both the gag-pol message as well as the 
genomic RNA The env-specific probe (F) hybridizes to the full-length viral 
mRNA, in addition to the 3.5-kb mRNA, suggesting that the 3.5-kb transcript may 
be the single-spliced mRNA encoding the EIAV env gene. Moreover, although 
not clearly observed in panel F due to the hybridization of the probe to a smear 
of degraded RNA below the 3.5-kb mRNA band, the results of separate 
experiments have revealed that probe F doesn’t hybridize to the 1.5-kb mRNA 
(data not shown). This indicates that probe F is complementary to an intron 
within the env gene which is not present in the 1.5-kb mRNA
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Each of the subgenomic probes representing sequences from the three 
short open reading frames (ORFs) SI, S2, and S3 (Dorn & Derse, 1988; Rushlow 
et al., 1986) (probes D, E, and G) hybridizes to all three virus-specific transcripts, 
suggesting that the 1.5-kb mRNA is presumably a double-spliced message 
containing sequences from the 5’-end of the genome and each of the ORFs SI, 
S2, and S3. It should be noted that a low molecular weight hybridizing RNA 
band, migrating at about 0.8- to 1.0-kb, is also detected by the 5’-LTR probe and 
each of the probes representing sequences from SI, S2, and S3 (probe A in panel 
A2, and probes D, E, and G). Because this band is not readily detected in 
Northern blots of 1.4% gels (e.g., probe A in panel Al), it is uncertain whether it 
actually represents a viral mRNA species or is a degradation product of the 
larger mRMA’s. Thus in this cytopathic EIAV infection three distinct virus- 
specific RNA species are detected in infected cells. Moreover, the levels of the
3.5-kb viral transcript appears to be much more abundant than that of the 8.2-kb 
or the 1.5-kb RNA’s, as observed previously by Northern blot analysis of total 
cellular RNA from infected FDD cells (Figure 8).
The differential steady-state levels of the viral RNA’s detected late in this 
cytopathic EIAV infection could be attributed to a temporally regulated, 
differential splicing of the genome-length RNA, resulting in relatively different 
concentrations of the various viral RNA species late during the infection. To 
examine this possibility, a time-course study was performed during which total 
cellular RNA isolated from FEK cells at 3-, 5-, 7-, and 9-days after infection with 
prototype EIAV and from FDD cells at 2-, 4-, 6-, 8-, 10-, and 12-days after
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infection with FDD-adapted EIAV, was subjected to Northern blot analysis using 
a mixture of probes A and G. As shown in Figure 10A, no viral transcripts are 
detected in infected FEK cells until 9-days after infection, and the earliest 
detectable RNA species, present at almost equal concentrations, are the full- 
length 8.2-kb and the spliced 3.5-kb transcripts. In infected FDD cells, however, 
viral transcripts are detectable as early as 2-days after infection, and the increase 
in their concentrations reaches a plateau at the sixth day of infection (Figure 
10B). It is evident that overproduction of the 3.5-kb spliced RNA occurs early 
during the cytopathic infection of FDD cells and does not appear to be 
temporally regulated. Moreover, it appears that the synthesis of the 1.5-kb mRNA 
may be temporally regulated as the levels of this transcript increase during the 
course of the cytopathic infection, with the highest level being detected at 12-days 
after infection.
II. CHARACTERIZATION OF THE SPLICING PATTERNS OF EIAV- 
SPECIFIC mRNA’S IN INFECTED CELLS 
cDNA Cloning and Sequencing
Nucleotide sequence analysis of the EIAV proviral DNA (Rushlow et al., 
1986; Stephens et al., 1986) has revealed the presence of putative splice donor 
and acceptor sites located throughout the viral genome. A schematic diagram of 
the location of the various putative splice donor and acceptor sites in relation to 
the six open reading frames of EIAV is presented in Figure 11 A.
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Figure 10. Time-course study on the synthesis of EIAV-specific transcripts. The 
numbers above each lane in panels A and B correspond to the time-points at 
which total RNA was isolated from infected cells (days post-infection). A  
Northern blot of total RNA isolated from FEK cells infected with prototype 
EIAV. B. Northern blot of total RNA isolated from FDD cells infected with 
FDD-adapted EIAV. In both panels 15.0 ug of total RNA, isolated at each time- 
point, was loaded on the appropriate lane of the gel. The positions of the 8.2-kb 
and the 3.5-kb viral RNA’s and of the 28S and 18S rRNA’s are indicated.
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Figure 11. Identification of clones containing the splice-junction cDNA of EIAV
3.5-kb mRNA.
A. Schematic diagram of the EIAV genome. Solid and open triangles 
represent the location of putative splice donor and acceptor sites, respectively. 
The location of the region within the env gene, to which the 30-mer 
oligonucleotide primer used for priming of first-strand cDNA synthesis is 
complementary, is also indicated. The small bar below ORFS2, denoted as "B-T', 
represents the 114-bp BamHL-Taql fragment of ORFS2 used for the initial 
screening of the cDNA library via colony hybridization. The small bar below the 
5’-LTR, denoted as "M-B", represents the 226-bp Mlul-BamHl 5’-LTR probe used 
for the secondary screening of the 16 EIAV-specific cDNA clones via Southern 
blot analysis.
B. Colony hybridization analysis of 213 random clones from the cDNA 
library which exhibited white phenotype on media containing X-gal. The probe 
used for this experiment was the 32P-labeled 114-bp BamHl-Taql fragment of 
ORFS2. Closed arrows point to positive controls for colony hybridization to the 
probe, which were E. coli DH5a colonies transformed with a recombinant pUC13 
plasmid containing the 114-bp BamHl-Taql fragment of ORFS2 as insert and 
exhibiting a white phenotype on media containing X-gal. These positive controls 
also served as markers on the autoradiogram for determining its correct 
orientation relative to the location of the clones taken from the cDNA library. 
Open arrows point to negative controls for colony hybridization to the probe,
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which were E. coli DH5a colonies transformed with pUC19 plasmid and 
exhibiting a blue phenotype on media containing X-gal.
C. Ethidium bromide-stained 1.0% agarose gel of Prfl-digested minilysate 
plasmid DNA isolated from the 16 EIAV-specific cDNA clones (lanes 1-16) 
which were identified in panel B by colony hybridization. Lane C contains a 
positive control for Southern blot hybridization of the gel to the 226-bp Mlul- 
BamHl probe, which was an Mlul/BamHl double-digested recombinant pIBI76 
plasmid containing the 226-bp Mlul-BamHl fragment as insert. Arrows above the 
gel point to cDNA clones 4 and 13, whose inserts were not cut out by Pstl.
D. Southern blot of the gel in panel C, hybridized to the 32P-labeled 226- 
bp Mlul-BamHl probe. Arrows above the blot point to cDNA clones 4 and 13, 
whose plasmid DNA strongly hybridized with the probe.
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With the availability of the Northern hybridization data, it was clear that 
the single-spliced 3.5-kb env mRNA is the predominant viral transcript during 
cytopathic infection of FDD cells. Moreover, since the 102-bp PvuU-Sspl fragment 
of ORFS1 was shown to hybridize to the 3.5-kb mRNA (Figure 9, panel D), it 
was clear that the splice acceptor site for this mRNA is located upstream of the 
Sspl site and thus, as expected, 5’ to the translational initiation codon of the env 
gene. Thus the exact splicing pattern of this mRNA was investigated by 
identification and sequencing of cDNA clones in a cDNA library constructed 
from poly(A)+ RNA of EIAV-infected FDD cells.
The cDNA library was constructed by utilizing a synthetic oligonucleotide, 
complementary to a 30-nucleotide-long sequence 400 nucleotides downstream of 
the initiation codon of the env gene, as the primer for first-strand cDNA synthesis 
(Figure 11A). The primer was designed to hybridize to RNA sequences within the 
env reading frame. Thus it was expected to hybridize to both the unspliced, 8.2-kb 
full-length mRNA, and the spliced, 3.5-kb env mRNA. Moreover, the 5’-to-3’ 
direction of first-strand cDNA synthesis, initiated from the primer towards the 5’- 
end of its complementary viral mRNA, was expected to generate cDNA copies of 
both the 8.2- and the 3.5-kb mRNA’s. Since the 3.5-kb mRNA splice acceptor site 
was known to be situated upstream of the env gene initiation codon, therefore 
cDNA copies of this mRNA were expected to span the splice junction of this 
transcript.
Following the synthesis of both first- and second-strand cDNA products, 
the double-stranded cDNA products were cloned into the plasmid vector pUC9
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and propogated in E. coli DH5a. Previous cDNA cloning experiments from 
poly(A)+ RNA of ELAV-infected cells had revealed that the first-strand cDNA 
synthesis reaction, under the conditions employed, results in a majority of the 
cDNA products being synthesized from cellular rather than viral mRNA’s (data 
not shown), most possibly due to non-specific hybridization of the oligonucleotide 
primer to cellular mRNA’s. To identify recombinant clones containing viral 
cDNA inserts, 213 independent clones of the library, exhibiting a white phenotype 
on media containing X-gal, were randomly selected and initially screened by 
colony hybridization using the 32P-labeled 114-bp BamHl-Taql DNA fragment of 
the env gene as the hybridization probe (Figure 11 A). This fragment contains 
DNA sequences immediately upstream of the priming site for first-strand cDNA 
synthesis, and the use of it as probe in the initial screening of the library 
permitted the identification of those clones which contained cDNA inserts 
generated from the priming site on ELAV-specific poly(A)+ RNA’s. The result of 
colony hybridization to the 114-bp BamHl-Taql probe is presented in Figure 11B, 
showing DNA from 16 of the 213 bacterial clones hybridizing to the probe. 
Because each clone was individually picked from the cDNA library and streaked 
on the nitrocellulose membrane used for colony hybridization analysis, differential 
intensities of the hybridization signal from the various clones are due to 
quantitative differences in sizes of the various colonies after their growth on the 
membrane, resulting from differences in either the growth rate of the individual 
clones or the number of viable bacteria transfered onto the membrane.
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A splicing event joins the R-U5-leader sequences from the 5’-end of the 
full-length genomic RNA to the splice acceptor site upstream of the env gene. 
Therefore it was apparent that among the 16 EIAV-specific cDNA clones, shown 
by colony hybridization to contain cDNA sequences located between the BamHl 
and Taql sites of the env gene, those possessing sequences spanning the splice 
junction of the 3.5-kb mRNA must also contain sequences from the 5’-region of 
the EIAV genome upstream of the gag gene. Thus the 16 EIAV-specific cDNA 
clones were subjected to a second round of screening using the radiolabeled 226- 
bp Mlul-BamHl fragment as the hybridization probe (Figure 11 A). The BamHl- 
end of the Mlul-BamHl probe is situated upstream of the three putative splice 
donor sites near the 5’-end of the gag gene (Figure 11 A), therefore it was clear 
that those clones hybridizing to this probe would contain cDNA sequences 
extending upstream of the BamHl site and thus would also span the splice 
junction of the 3.5-kb mRNA.
The cloning strategy used for the generation of the cDNA library was 
based on oligo(dC)-tailing of the double-stranded cDNA products, in the presence 
of deoxycytidine and terminal deoxynucleotidyl transferase, followed by annealing 
of the oligo(dC)-tailed cDNA to /M-linearized, oligo(dG)-tailed pUC9. In such a 
manner, a Pstl site is created at each end of the cDNA insert within the pUC9 
vector, allowing recovery of the cDNA insert by a Pstl digestion of the plasmid 
DNA. Thus minilysate plasmid DNA, prepared from the 16 positive clones, was 
digested with Pstl to release the cDNA inserts, fractionated by electrophoresis 
through a 1.0% agarose gel, and Southern blotted using the 226-bp Mlul-BamHl
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probe. Figure 11C shows the ethidium bromide-stained 1.0% agarose gel of the 
Ptfl-digested minilysate plasmid DNA from the 16 EIAV-specific cDNA clones 
(lanes 1-16). As a positive control for the hybridization of the Southern blot of 
the same gel to the 226-bp Mlul-BamHl probe, the pIBI76 plasmid DNA 
containing the 226-bp Mlul-BamHl fragment was digested with Mlul and BamHl 
and loaded on lane C of the gel. Digestion of this plasmid with Mlul and BamHl 
yields two DNA fragments: a 4200-bp linearized pIBI76 vector DNA and a 226- 
bp Mlul-BamHl fragment (Figure 11C, lane C). Digestion of the minilysate 
plasmid DNA from the 16 EIAV-specific cDNA clones with Pstl yields a 2700-bp 
linearized pUC9 vector DNA, a 1500- to 1700-bp undigested plasmid DNA and 
the cDNA inserts of the individual clones, ranging from 400- to 1000-bp in size 
(Figure 11C, lanes 1-16). Interestingly, the cDNA inserts in plasmid DNA of 
clones 4 and 13 (Figure 11C, lanes 4 and 13, marked by arrows) are not excised 
from the vector following the Pstl digestion. Additional restriction enzyme 
mapping of plasmid DNA from these two clones indicated that they were 
identical and revealed a deletion of one of the two Pstl sites present at each end 
of the cDNA insert, thus explaining the inability of the Pstl digestion to release 
their cDNA inserts.
The Southern blot of the same gel, hybridized to the 226-bp Mlul-BamHl 
probe, is presented in Figure 11D. Out of the 16 EIAV-specific cDNA clones, 
only plasmid DNA from clones 4 and 13, which contain a deleted Pstl site, 
hybridizes with this probe (Figure 11D, lanes 4 and 13, marked by arrows). As 
can be seen, the probe hybridizes with two specific DNA bands in lanes 4 and 13
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of Figure 11D. The slower migrating band is the Ryfl-linearized plasmid DNA of 
each of the two clones, while the faster migrating band is undigested plasmid 
DNA. Since the cDNA insert is not excised by Pstl due to a deleted Pstl site in 
plasmid DNA of these two clones, the cDNA sequence is therefore present in 
both the P&I-linearized and the undigested plasmid DNA bands. Thus the probe, 
recognizing the cDNA sequence present in both DNA bands, strongly hybridizes 
with both. Moreover, the particular preparation of the 226-bp Mlul-BamHl probe 
used in this experiment also contained low amounts of contaminating vector 
DNA, as evidenced by the weak hybridization of the probe to the pIBI vector 
DNA band in addition to the 226-bp Mlul-BamHl fragment in the control sample 
(Figure 11D, lane C). Since the labeled contaminating pDBI vector DNA present 
in the probe preparation also contains a pBR322-derived sequence present in 
pUC9 DNA, it also recognizes the linearized and undigested pUC9 DNA 
fragments of clones 1-3, 5-12, and 14-16 (Figure 11D, lanes 1-3, 5-12, 14-16), thus 
explaining the weak hybridization of these fragments to the probe. The 
hybridization of plasmid DNA from these latter 14 clones only to the 114-bp 
BamHl-Taql probe (Figure 11B), and not to the 226-bp Mlul-BamHl probe 
(Figure 11D), indicated that their cDNA inserts had primed from the 8.2-kb full- 
length EIAV mRNA and thus had extended into the pol gene instead of spanning 
the splice junction of 3.5-kb mRNA.
The hybridization of plasmid DNA from clones 4 and 13 to the 226-bp 
Mlul-BamHl probe indicated that they contained cDNA inserts extending 
upstream of the gag gene and thus spanning the splice junction of the 3.5-kb
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mRNA. This finding was further confirmed by restriction enzyme mapping of 
plasmid DNA from these two clones using restriction enzymes Smal and BamHl. 
The distance between the Smal site upstream of the gag gene and the BamHl site 
near the 5’-end of the env gene on the EIAV proviral DNA is 4945-bp. However, 
a Smal/BamHl double-digestion of plasmid DNA from both clones had yielded a 
270-bp fragment (data not shown), clearly indicating that a splicing event between 
the Smal site, upstream of the gag gene, and the BamHl site, near the 5’-end of 
the env gene, had reduced the distance separating the two restriction sites from 
4945-bp on the provirus to 270-bp on the cDNA.
The 270-bp Smal-BamHl fragment from both cDNA clones was subcloned 
into M13mpl8 and M13mpl9 RF DNA, allowing nucleotide sequencing of both 
strands of each clone by the dideoxy chain termination method (Sanger et al., 
1977). The two clones were found to contain identical splice sites, and the 
nucleotide sequence of the splice junction present in both clones is presented in 
Figure 12A The sequencing data identifies the splice donor and acceptor sites, in 
the full-length EIAV genomic mRNA, used to generate the spliced mRNA copy 
of the two cDNA clones. Of the three potential splice donor sites near the 5’- 
terminus of the gag gene (Figure 12B; see below), in this spliced mRNA the 5’- 
most splice donor site is spliced to the splice acceptor site near the 5’-end of 
ORFS1, 178 nucleotides upstream of the env gene translational initiation ATG 
codon. Also shown in Figure 12B are the nucleotide sequences of the identified 
splice donor and acceptor sites and the extent of their homology to the consensus 
splice donor and acceptor sequences (Mount, 1982; Ohshima and Gotoh, 1987).
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Figure 12. Nucleotide sequence analysis of the 270-bp Smal-BamHl splice- 
junction cDNA of the EIAV 3.5-kb mRNA.
A. Autoradiogram of a sequencing gel showing the region of nucleotides 
immediately 5’- and 3’- to the splice junction site, which is pointed out by the 
arrow.
B. Schematic diagram of the EIAV genome, showing the location of 
putative splice donor sites (solid triangles) and acceptor sites (open triangles) on 
the viral genome. The bold-face nucleotide sequences within the left and right 
lower brackets are those of the identified splice donor and acceptor site, 
respectively, with underlined bases showing perfect homology to the consensus 
donor and acceptor site sequences (Mount, 1982; Ohshima and Gotoh, 1987). The 
arrows show the site of splicing.
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Northern Hybridization Analysis Using Splice Donor-Specific Oligonucleotide 
Probes
As mentioned previously, three potential splice donor sites are located 
near the 5’-terminus of the EIAV gag gene (Figure 12B) based on matches to the 
consensus sequence for splice donor sites (Mount, 1982; Ohshima and Gotoh, 
1987). Based on the utilization of one or more of the three donor sites for 
generation of the spliced viral transcripts, a number of differentially spliced 
mRNA’s can be generated in EIAV-infected cells with varying coding potentials. 
The nucleotide sequence of the three short ORFs in the EIAV genome has 
revealed that only S2 contains a translational initiation methionine codon 
(Rushlow et al., 1986). Thus for functional expression of SI or S3, an initiation 
codon from an upstream gene needs to be spliced, in frame, to the coding 
sequences of the two ORF’s.
By comparison to other lentiviruses, which utilize multiple splicing of their 
full-length genomic mRNA to generate the small mRNA’s needed to encode their 
short ORFs (Arya et al., 1985; Arya and Gallo, 1986; Davis and Clements, 1989; 
Mazarin et al., 1988; Muesing et al., 1985), the initiation codon for the EIAV SI 
or S3 ORFs would be assumed to be located within the first exon of such multi­
spliced mRNA. This exon would contain sequences from the 5’-region of the viral 
genome, and the only translational initiation ATG codon in this region is that of 
the gag gene.
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The nucleotide sequence of the EIAV provirus near the 5’-terminus of the 
gag gene is presented in Figure 13 (Stephens et al., 1986). The sequence starts 
from the Smal site, 71 nucleotides upstream of the gag gene’s ATG translational 
initiation codon, and continues for 120 nucleotides (40 codons) into gag. 
Moreover, the location of each of the three putative splice donor sites in relation 
to the gag ATG codon is shown with underlined bases in each donor site 
representing a perfect match to the consensus donor site sequence (Mount, 1982; 
Ohshima and Gotoh, 1987). As can be seen, the 5’-most donor site is an excellent 
match with the consensus sequence except in the last position; the middle donor 
site is a very good match with the consensus sequence with the exception of the 
last two nucleotides; and the 3’-most donor site is a good match with the 
consensus sequence except in the second and the eighth positions.
Furthermore, as shown in Figure 13, the 5’-most splice donor site is 
situated immediately upstream of the gag ATG codon, and its utilization in a 
splicing event would remove the gag initiation codon, as part of the intron, from 
the spliced mRNA. Since the other two putative splice donor sites are located 
downstream of the gag ATG codon, potential splicing events utilizing either one 
of these two donor sites, however, would result in the ATG codon of gag being 
retained in the spliced mRNA.
Although the use of the 5’-most splice donor site for generation of a 
spliced EIAV mRNA was already determined by cDNA cloning and sequencing, 
this finding does not rule out the potential utilization of either of the other two 
putative splice donor sites to generate additional alternatively spliced
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Figure 13. Nucleotide sequence of the EIAV provirus near the 5’-terminus of the 
gag gene (Stephens et al., 1986). The sequence starts from the Smal site, 71 
nucleotides upstream of the gag gene’s ATG translational initiation codon, and 
continues for 120 nucleotides (40 codons) into gag. The sequences within each of 
the three putative splice donor sites are in bold-face, with underlined nucleotides 
in each donor site representing a perfect match to the consensus donor site 
sequence (Mount, 1982; Ohshima and Gotoh, 1987), which is shown at the 
bottom of the figure. Solid triangles above each donor site show the expected site 
of splicing. Brackets above the EIAV DNA sequence and immediately upstream 
of each donor site sequence contain the sequences the three oligonucleotides, SD- 
1, SD-2, and SD-3, which were used as probes in Northern hybridization analysis. 
One-letter amino acid codes below each the gag gene codons, beginning with the 
ATG methionine codon, denote the amino-terminal sequence of the gag 
polyprotein.
84
SD-1
I 3 1-CTCCACAAGGACCGGTCTTGTGI
Steal
£££GGGACAGCAGAGGAGAACTTACAGAAGTCTTCTGGAGGTGTTCCTGGCCAGAACAC
_________________ SD-2____________________
lTCCTCC-5~n 13 ’ -CCTCTGGGAAACTGTACCTCGTTCCGCG-5'TI
T
AGGAGGACAGGTAAGATGGGAGACCCTTTGACATGGAGCAAGGCGCTCAAGAAGTTAGAG
M G D P L T W S K A L K K L E
________________ SD-3____________________
| 3 ' -CCATGTTCCCAGAGTCTTTAATTGATG-51 I
▼ ?
AAGGTGACGGTACAAGGGTCTCAGAAATTAACTACTGGTAACTGTAATTGGGr.GGTAAGT
K V T V Q G S Q K L T T G N C N W A L S
C TAG TAGAC T TAT T T ____
L V  D L P
Consensus splice donor sequence: ^ACaGT^AGT
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EIAV mRNA’s in infected cells. For instance, the 3.5-kb mRNA could represent 
a heterogeneous population of mRNA molecules generated by splicing of each of 
the three donor sites to the same acceptor site upstream of the env gene, or by 
splicing of one donor site to different, but proximally located, acceptor sites 
upstream of the env gene. As a direct method for addressing the first possibility, 
that is differential splicing of the three donor sites to the same acceptor site, 
oligonucleotides complementary to sequences immediately upstream of each of 
the three splice donor sites were radiolabeled with 32P and used as probes in 
Northern hybridization analysis of poly(A)+ RNA from infected FDD cells. The 
sequence of the three oligonucleotides, termed SD-1, SD-2, and SD-3, along with 
the location of their complementary region upstream of each splice donor site on 
the viral genome is also indicated in Figure 13.
Since all three probes contain complementary sequences to the full-length 
genomic mRNA, they would all be expected to hybridize to this viral transcript. 
Moreover, because SD-1 is complementary to a region upstream of all three 
putative splice donor site, it is expected to also hybridize to all spliced viral 
mRNA’s, namely the 3.5- and 1.5-kb mRNA’s, whose production would utilize 
either one, two, or all three of the donor sites downstream of SD-1. Furthermore, 
the hybridization of SD-2 to either the 3.5- or the 1.5-kb mRNA, or to both, 
would indicate that the middle splice donor site, in addition to the 5’-most donor 
site, is utilized to generate the corresponding spliced viral mRNA(s). Similarly, 
the hybridization of SD-3 to either of the two spliced mRNA’s, or to both, would 
reveal the usage of the 3’-most donor site, in additon to the 5’-most donor site,
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for generation of the corresponding viral mRNA(s). However, the hybridization of 
SD-2 and SD-3 to only the full-length 8.2-kb mRNA, and not to any spliced 
mRNA, would indicate that only the 5’-most splice donor site is used to generate 
the 3.5- and 1.5-kb mRNA’s of EIAV.
The results of the three Northern hybridizations are presented in Figure 
14. As expected, SD-1 hybridizes to the three species of EIAV-specific mRNA’s. 
However, SD-2 and SD-3 only hybridize to the 8.2-kb full-length mRNA and do 
not detect either the 3.5- or the 1.5-kb spliced mRNA’s recognized by SD-1.
These results indicate that the 5’-most splice donor site, already shown to be used 
for generating a spliced EIAV mRNA, is the only donor site utilized in EIAV- 
infected FDD cells for splicing of the full-length viral genomic mRNA. Thus the 
R-U5-leader sequences initiating from the 5’-boundary of the R region and 
terminating at the 5’-most splice donor site constitute the first exon of all spliced 
EIAV mRNA’s. The consequences of this finding are that spliced EIAV mRNA’s 
containing sequences from ORFS1 or ORFS3 lack the gag gene AUG codon, and 
if these short ORFs are indeed expressed in EIAV-infected cells, translation of 
their corresponding mRNA’s would presumably have to involve the use of non- 
AUG initiation codons.
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8.2
3.5
1.5-
Figure 14. Northern hybridization analysis of poly(A)+ RNA from EIAV-infected 
FDD cells using the three oligonucleotide probes SD-1, SD-2, and SD-3 (lanes 1, 
2, and 3, respectively). The electrophoretic mobilities of the three species of 
ELAV-specific mRNA’s are indicated on the left.
i  :
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SI Nuclease Mapping of Viral mRNA’s
The results of Northern hybridizations with the splice donor-specific 
oligonucleotide probes indicated that all spliced EIAV mRNA’s utilize the 5’- 
most splice donor site immediately proceeding the gag gene. Moreover, the results 
obtained from cDNA cloning and sequencing had revealed the splicing of this 
donor site to the acceptor site 178-nucleotides upstream of the 5’-boundary of the 
env gene to generate the single-spliced 3.5-kb env mRNA.
By analogy to other lentiviruses, it is presumed that the majority of 
sequences within the EIAV single-spliced mRNA, lying outside of those within 
the short ORFs, would be removed as an intron in a second splicing event to 
produce the double-spliced viral mRNA (Aiya et al., 1985; Arya and Gallo, 1986; 
Davis and Clements, 1989; Mazarin et al., 1988; Muesing et al., 1985). The 
double-spliced message, containing coding sequences of the short ORFs, would 
then encode the regulatory proteins of the virus such as the viral trans- 
activator(s). Indeed a 1.4-kb cDNA copy of one such double-spliced mRNA, 
containing sequences from ORFS1 and ORFS3, has already been isolated and 
shown to encode a viral fra/tr-activator (Derse et al., 1989; see below). Moreover, 
in agreement with our finding that only the 5’-most splice donor site on the EIAV 
genome, upstream of the gag gene AUG codon, is utilized to generate the first 
exon of all virus-specific spliced mRNA’s in infected cells, the translation of the 
aforementioned double-spliced viral mRNA is proposed to be initiated from a 
non-AUG codon (Derse et al., 1989).
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To map the location of the splice donor site(s) within the EIAV env gene 
that are used to produce the double-spliced mRNA species, and also to 
determine whether any additional splice acceptor sites, located upstream of and 
within the env gene, are used to generate the spliced EIAV mRNA’s, Sl-nuclease 
mapping studies were performed using RNA from FDD cells infected with FDD- 
adapted EIAV. The studies were designed to also include the 5’-region of the gag 
gene to test the validity of the results obtained previously using the splice donor- 
specific oligonucleotide probes.
Figure 15 shows the relative location of putative splice donor and acceptor 
sites, represented by closed and open triangles, respectively, on the EIAV 
genome. In addition to the acceptor site located 178-nucleotides upstream of the 
env gene initiation codon and identified by cDNA cloning and sequencing, a 
second putative acceptor site is present at 129-nucleotides upstream of the env 
initiation codon. Following the 3’-terminus of ORFS1 and extending into the 
coding sequences of ORFS2 are four putative donor sites, any one of which could 
potentially be utilized in the second splicing event of the single-spliced 3.5-kb 
mRNA to generate a double-spliced 1.5-kb mRNA. Moreover, a putative splice 
acceptor site is situated immediately at the 5’-boundary of the ORFS3 reading 
frame.
The sequence of each putative donor and acceptor site, with the exception 
of the three putative donor sites near the 5’-terminus of the gag gene whose 
sequence was presented earlier in Figure 13, is presented in Table III. In each 
case, underlined bases correspond to a perfect match with the consensus donor
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5'LTR
3'LTR
pol
Figure 15. Schematic diagram of the EIAV genome. The figure shows the 
location of putative splice donor and acceptor sites, represented by solid and 
open triangles, respectively, on the viral genome.
Table m . Nucleotide sequence of the putative splice donor and
acceptor sites located immediately upstream of or within the 
EIAV env genea.
Nucleotide sequence of 
putative splice sites
Nature of splice site Position on the 
EIAV genome^
M.GLrrT<2A Donor 1226
TTG^TAAAG Donor 1248
TGGGGTAACA Donor 1256
ACjJ gTAAGA Donor 1385
VTTG AGTATTGTTGCAGG Acceptor^ 1084
V
TTCCTGAGGTCTCT AGG Acceptor 1133
VAACCTCTTCGCCTAAGA Acceptor 3184
a. The splice junction site within the putative donor and acceptor 
sequences is denoted by closed and open triangles, respectively. 
Underlined nucleotides are a perfect match with the consensus 
splice junction sequences (Mount, 1982; Ohshima and Gotoh,
1987).
b. Based on the numbering system of Rushlow et al. (1986).
c. The utilization of this acceptor site in prototype EIAV-infected FDD 
cells has already been confirmed by cDNA cloning and sequencing 
(Figure 11).
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and acceptor site sequences (Mount, 1982; Ohshima and Gotoh, 1987). Both 
acceptor sites located upstream of the env gene show an excellent match with the 
consensus acceptor site sequence. Moreover, the four putative donors which 
follow the 3’-end of ORFS1 and extend into ORFS2 exhibit good matches with 
the consensus donor sequence. Finally, the acceptor site located immediately at 
the 5’-boundary of the ORFS3 reading frame is a good match with the consensus 
sequence but contains an A instead of a G in the +1 position and an A instead 
of a pyrimidine in the -3 position.
For SI nuclease mapping studies of the splice donor and acceptor sites in 
spliced viral mRNA’s, four specific EIAV proviral DNA restriction fragments, 
spanning the various putative splice donor and acceptor sites on the viral genome, 
were used as probes. Since the entire nucleotide sequence within each of the four 
probes comes from the EIAV proviral DNA, the full-length nonsense strand of 
each probe is complementary to the sense strand sequence of the unspliced, full- 
length 8.2-kb EIAV genomic mRNA. Moreover, by virtue of spanning the 
putative splice donor or acceptor sites on the full-length genomic mRNA, only a 
segment of the nucleotide sequence within the nonsense strand of each probe is 
complementary to the corresponding exon sequence of the full-length viral mRNA 
and its spliced mRNA product. The other segment of the nonsense strand of the 
respective probe, however, is complementary to the corresponding intron 
sequence of the full-length viral mRNA which is not present in its spliced 
product. Such differential complementarity of each splice junction probe to the
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unspliced and spliced viral mRNA’s provides the basis for mapping the exact 
location of splice donor and acceptor sites on the viral genome.
Following the hybridization of each denatured probe to RNA from EIAV- 
infected cells, a protection assay is performed in which the RNA-DNA hybrid is 
treated with the single-strand-specific nuclease SI. Single-stranded probe DNA or 
viral RNA is degraded by the nuclease into mononucleotides while double­
stranded DNA or RNA-DNA hybrids are left intact (Berk and Sharp, 1977). Thus 
in this assay the full-length probe fragment is expected to be protected from SI 
nuclease digestion by the full-length viral genomic mRNA, while smaller probe 
fragments would be rescued from SI nuclease digestion by the spliced viral 
mRNA’s. The size of the smaller probe fragments, determined by denaturing 
polyacrylamide gel electrophoresis, would then be equal to the actual distance 
between the splice site on the spliced mRNA relative to the radiolabeled end of 
the probe.
Figure 16A presents a schematic diagram of the EIAV genome, showing 
the location of the four probes used for SI nuclease mapping studies relative to 
the putative splice donor and acceptor sites on the viral genome. Because the 
probes are radiolabeled double-stranded DNA fragments, in each hybridization 
reaction a portion of the denatured nonsense strand input probe molecules re- 
hybridize back to their complementary sense DNA strand instead of hybridizing 
to viral mRNA’s. Such full-length nonsense strand probe molecules cannot be 
distinguished from those that are protected from SI nuclease digestion by the full- 
length mRNA. To allow for distinction of the full-length input probe from the
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Figure 16. Schematic representation of the probes used in SI nuclease mapping.
A. Schematic diagram of the EIAV genome, showing the location of the 
four probes used for SI nuclease mapping studies (pi, p2, p3, p4) relative to the 
location of putative splice donor (solid triangle) and acceptor sites (open triangle) 
on the viral genome. Probe p i consists of a 300-bp Narl-Pvull proviral DNA 
fragment and a 250-bp M13mpl8 PvuU-Narl tag fragment at the Pvull site. Probe 
p2 consists of a 450-bp NcoI-BamHL proviral DNA fragment and a 161-bp 
M13mpl9 Ncol-Bglll tag fragment at the Ncol site. Probes p3 and p4 do not 
contain tag sequences and were directly used in S 1-nuclease protection analysis as 
617-bp PvuU-HindlU and 385-bp Dral-Scal proviral DNA restriction fragments, 
respectively. Abbreviations: N, Nar\\ P, Pvull; G, BglII; C, Ncol; B, BaraHI; P, 
Pvull; H, Hindlll; D, Dral; S, Seal; SD, putative splice donor site(s); SA, putative 
splice acceptor site(s).
B.-E. Schematic representations of probes pl-p4, respectively. Also shown 
in each panel are fragments of the nonsense strand of each respective probe, and 
their lengths in nucleotides (nt), which could potentially be protected from SI 
nuclease digestion by the unspliced, single-spliced, and double-spliced EIAV 
mRNA’s. The asterisk represents the 32P-labeled end of the nonsense strand of 
each probe.
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probe fragment rescued by the full-length mRNA, two of the probes were 
specifically designed to contain "tag" sequences taken from the double-stranded 
replicating form (RF) DNA of either M13mpl8 or M13mpl9 and attached to 
their intronic end. As shown in Figure 16B, probe 1 (pi) consisted of a 300-bp 
Narl-PvuTL proviral DNA fragment and a 250-bp M13mpl8 Smal-Narl tag at the 
Pvull site. Thus following S 1-nuclease protection analysis using this probe, the 
input probe and the probe fragment rescued by the full-length mRNA would be 
550- and 300-nucleotides (nt) long, respectively. Moreover, smaller probe 
fragments, whose size equals the distance between the splice donor site and the 
JVorl-end of the probe, would be protected from S 1-nuclease digestion by the 
spliced mRNA’s. This distance is 130-nt for the 5’-most donor site, 183-nt for the 
middle donor site, and 217-nt for the 3’-most donor site.
Similarly, as shown in Figure 16C, probe 2 (p2) consisted of a 450-bp 
Ncol-BamHl proviral DNA fragment and a 161-bp M13mpl9 Smal-BgRl tag at 
the repaired Ncol site. Thus following S 1-nuclease protection analysis using this 
probe, the expected length of the input probe would be 611-nt while the probe 
fragment protected by the full-length mRNA would be 450-nt long. In additon, 
the distance between each of the two putative splice acceptor sites in this region 
and the BamHl-end of the probe is 157- and 206-nt long, respectively.
The other two probes, probes p3 and p4, did not contain tag sequences 
and were directly used in Sl-nuclease protection analysis as 617-bp PvuU-Hindlll 
and 385-bp Dral-Scal proviral DNA restriction fragments, respectively. As shown
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in Figure 16D, the distance between each of the four putative splice donor sites 
located within the sequences of probe p3 and the fVuII-end of this probe is 114-, 
136-, 144-, and 273-nt long, respectively. Moreover, Figure 16E shows the the 
distance between the putative acceptor site located within the sequences of probe 
p4 and the Scal-end of the probe, which is 178-nt long.
For SI nuclease protection assays, RNA-DNA hybrids, obtained from 
hybridization of each end-labeled probe with total RNA isolated from FDD cells 
infected with FDD-adapted EIAV, were digested with SI nuclease and the 
digestion products were resolved on 6% polyacrylamide-8M urea sequencing gels. 
As negative control, RNA from uninfected FDD cells, lacking EIAV-specific 
unspliced and spliced transcripts, was used in parallel experiments. The results of 
these studies are presented in Figure 17.
Panels A, B, C, and D in Figure 17 correspond to individual S 1-nuclease 
protection assays using probes pi, p2, p3, and p4, respectively, which were 
described above. In each panel, lane M contains end-labeled MspI fragments of 
plasmid pBR322, while lane 1 or lane 2 contain the corresponding probe 
fragments protected from SI nuclease digestion by RNA from EIAV-infected 
FDD cells or uninfected FDD cells, respectively. In panel A, three distinct 
fragments of probe p i (550-bp Narl\ Figure 16A and 16B), migrating at about 
550-nt, 300-nt, and 130-nt are protected following the Sl-nuclease protection assay 
utilizing RNA from infected cells (lane 1), while only the 550-nt full-length probe 
fragment is present following the assay in which control RNA from uninfected 
cells is utilized (lane 2). The 550-nt probe fragment in lanes 1 and 2 corresponds
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Figure 17. SI nuclease mapping of splice junctions in spliced mRNA’s of EIAV. 
Panels A, B, C, and D correspond to SI nuclease protection assays of probes pi, 
p2, p3, and p4, respectively, using total cellular RNA from FDD cells infected 
with FDD-adapted EIAV (lane 1), or uninfected FDD cells (lane 2), Lane M in 
each panel contains 32P-labeled Mspl-digested pBR322 as size marker.
99
A
nt
022_
527~  ■
404-
309-  * * *
23
217-  * »  
201-  «, 
100-  «■ 
180-  * »
160-  m  
147-  m
B C D
M l  2 M l  2 M 1 2
m i* *  m
^Sn& SrI F r  « |
•  •  w
•  •
J|4
123-  « *  
110— <•» W
90-  •
76-  •  
67-  • <*
100
to the portion of full-length input probe molecules, containing the M13 tag 
sequence, which have escaped degradation by SI nuclease due to re-hybridization 
with their complementary DNA strand. Moreover, the additional probe fragments 
present in lane 1, but not in lane 2, are those which have been protected from 
Sl-nuclease degradation by EIAV-specific mRNA’s. In lane 1, the 300-nt 
fragment of the probe is that which is protected by the full-length 8.2-kb EIAV 
mRNA (Figure 16B), while the 130-nt probe fragment is that which is protected 
by a spliced viral mRNA whose splice junction site is 130-nt downstream of the 
Afarl-end of the probe within the EIAV genome. This splice site corresponds 
exactly to the 5’-most donor site among the three putative donor sites near the 5’- 
end of the EIAV gag gene (Figure 16A). Furthermore, as mentioned above, the 
protected probe fragments which would correspond to spliced mRNA’s utilizing 
the middle or the 3’-most putative donor sites in this region would be expected to 
be 183- or 217-nt long (Figure 16A and 16B). Since these additional bands are 
not present in lane 1 of panel A, it appears that the 5’-most splice donor site is 
indeed the only donor site near the 5’-end of the gag gene that is utilized in 
EIAV-infected FDD cells for splicing of the full-length viral mRNA, confirming 
the earlier results obtained using the splice-donor-specific oligonucleotide probes.
In Figure 17, panel B, four distinct fragments of probe p2 (611-bp BamHl- 
BglU; Figure 16A and 16C), migrating at about 611-nt, 450-nt, 206-nt, and 155-nt 
are protected by RNA from infected cells (lane 1). As expected, the 611-nt full- 
length probe fragment, containing the M13 tag sequence, is the only protected 
probe fragment in the assay utilizing RNA from uninfected cells (lane 2). In lane
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1 of panel B, the 450-nt fragment of the probe is that which is protected by the 
full-length 8.2-kb EIAV mRNA, while the probe fragments migrating at about 
206-nt and 155-nt are those protected by spliced viral mRNA’s whose splice 
junction sites are therefore 206-nt and 155-nt, respectively, upstream of the 
BamHl-end of the probe. The higher intensity of the 206-nt probe fragment 
corresponds to the higher concentration of the viral mRNA which has protected 
this fragment relative to the other viral mRNA’s present in infected FDD cells. 
The splice junction site located at 206-nt upstream of the BaniHl site corresponds 
exactly to the acceptor site, already identified by cDNA cloning and sequencing, 
which is located at 178-nt upstream of the env gene initiation codon (position 
1084 on the nucleotide sequence of Rushlow et al., 1986; Table IB). Interestingly, 
the second splice junction site identified by this assay and located at 155-nt 
upstream of the BamHI-end of the probe corresponds to the acceptor site present 
at 129-nt upstream of the env gene initiation codon (position 1133 on the 
nucleotide sequence of Rushlow et al., 1986; Table III). The length of the probe 
fragment protected by a spliced mRNA utilizing this acceptor site was actually 
expected to be 157-nt (Figure 16C), although the apparent mobility of this 
fragment is closer to 154- or 155-nt during denaturing polyacrylamide gel 
electrophoresis (Figure 17, panel B, lane 2).
Panel C in Figure 17 shows the results of SI nuclease protection analysis 
of probe p3 (617-bp PvuU-HindUl; Figure 16A and 16D). As expected, the full- 
length 617-bp probe fragment is protected by RNA from either infected or 
uninfected FDD cells (lanes 1 and 2). Moreover, a protected probe fragment,
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migrating at about 140- to 144-nt, is protected by RNA from infected cells (lane 
1) but not by RNA from uninfected cells (lane 2). This fragment of the probe is 
therefore protected by a spliced EIAV mRNA whose splice junction site is 
situated at about 140- to 144-nt downstream of the Pvull site on the viral 
genome. As mentioned previously, the four putative splice donor sites near the 
end of ORFS1 and within the sequences of the Pvull-Hindlll probe (p3) are 
located at 114-, 136-, 144-, and 273-nt from the fVnll-end of the probe. Since the 
mobility of the protected probe fragment identified in this assay corresponds to a 
fragment of about 140- to 144-nt, the donor site located at 144-nt from the Pvull- 
end of the probe (position 1256 on the nucleotide sequence of Rushlow et al., 
1986; Table III) appears to be the donor site used to generate a spliced EIAV 
mRNA which has protected this fragment of probe p3.
Finally, in Figure 17, panel D, the full-length probe p4 (385-bp Dral-Scal; 
Figure 16A and 16E) is protected from SI nuclease digestion by RNA from either 
infected or uninfected FDD cells (lanes 1 and 2), while an additional fragment of 
the probe migrating at about 180-nt is only protected by RNA from infected cells 
(lane 1). Therefore the 180-nt probe fragment is one which is protected from SI 
nuclease digestion by a spliced EIAV mRNA whose splice junction site is 180-nt 
upstream of the Seal site on the viral genome. The only splice junction site in this 
region of the viral genome is a putative splice acceptor site situated at the 5’- 
boundary of ORFS3 (Figure 16A; position 3184 on the nucleotide sequence of 
Rushlow et al., Table III). This acceptor site is exactly 178-nt upstream of the 
Scal-end of the Dral-Scal probe (p4), and a spliced mRNA generated by the
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utilization of this acceptor site would be expected to protect a 178-nt fragment of 
the probe (Figure 16E). The apparent mobility of the protected probe fragment 
during denaturing polyacrylamide gel electrophoresis, although closer to 180-nt 
than to 178-nt, suggests that this splice acceptor site is indeed utilized in EIAV- 
infected FDD cells to generate a spliced viral mRNA which has protected the 
180-nt probe fragment.
Longer exposures of the autoradiograms in panels A, B, C, and D of 
Figure 17 did not reveal any additional protected probe fragments (data not 
shown), suggesting that the detected EIAV mRNA’s constitute the major species 
of viral transcripts present in infected FDD cells. The SI nuclease mapping 
studies described above have confirmed the earlier results obtained through 
Northern hybridizations using the splice donor-specific oligonucleotide probes, 
showing that the 5’-most splice donor site, immediately upstream of the gag gene, 
is the common donor site to all spliced EIAV mRNA’s. Moreover, in addition to 
the splice acceptor site previously identified by sequencing of splice-junction 
cDNA obtained from the 3.5-kb mRNA, the SI nuclease mapping studies have 
identified and localized a second splice acceptor site upstream of the env gene, a 
splice donor site immediately downstream of ORFS1, and a splice acceptor site at 
the 5’-boundary of ORFS3.
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III. The 3.5-kb EIAV mRNA: Potential To Encode The ORFS2 Gene Product In 
Addition To The env Proteins
Based on the nucleotide sequence of the EIAV proviral DNA, the 
predicted amino acid sequences of the three short ORFs of EIAV is presented in 
Figure 18 (Rushlow et al., 1986). As with the short ORFs of other lentiviruses, 
such as HTV-1 or visna virus, whose encoded products have been generally shown 
to code for tram -acting viral regulatory proteins (Arya et al., 1985; Davis and 
Clements, 1989; Mazarin et al., 1988; Sodroski et al., 1986), attempts to delineate 
the function of the three short ORFs of EIAV have mainly focused on assessing 
the ability of their gene products to fram-activate the viral LTR. Based on the 
results of early deletion mutagenesis experiments, by which parts of the coding 
sequence within each ORF were removed and the resulting mutant proviruses 
were assayed for their capacity to tram-activate the viral LTR, sequences within 
the pol-env intergenic region on the viral genome, to which both SI and S2 
belong, were shown to be required for fraro-activation of the viral LTR (Sherman 
et al., 1988). More recently, Derse et al. (1989) have isolated a cDNA clone of a 
double-spliced EIAV mRNA, containing sequences from SI and S3, and have 
shown that it can fra/u-activate the viral LTR in transfected cells. Since the 
coding sequence of SI is located in the pol-env intergenic region, it is therefore 
presently believed that SI encodes a viral tram-activating protein. The function of 
the other two ORFs, however, is not known and to date no protein products 
from any of the three ORFs have been detected in EIAV-infected cells.
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ORFS1
V L L Q VE A R P N Y H C Q L C F L R S L VG I D Y L D A S L R K K N K
Q R L K A I Q Q G R Q P Q Y L L
ORFS2
Y M G L F G K G V T W S A S H S M G G S Q G E S Q P L L P N S Q K
N L S V R R T Q C F N L I V I I M T V R T A W Q N R R K Q E T K K
ORFS3
VD P Q G P L E S D Q W C R V L R Q S L P E E K I P S Q T C I A R R H
L G P G P T Q H T P S R R D R W I R G Q I L Q A E V L Q E R L E W R
I R G V Q Q A A K E L G E V N R G I W R E L Y F R E D Q R G D F S
A W G G Y Q R A Q E R L W G E Q S S P R V L R P G D S K R R R K H
L
Figure 18. Predicted amino acid sequences of the three short ORFs of EIAV.
The sequences are "translated" from the nucleotide sequence of EIAV proviral 
DNA (Rushlow et al., 1986). The splice acceptor sites in SI and at the 5’- 
boundary of S3, identified by sequencing of splice-junction cDNA and SI nuclease 
mapping, are indicated by open triangles.
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A unique property among these short ORFs is that S2 is the only one 
which contains a translational initiator ATG codon, located at its second codon 
position (Figure 18). Thus, because SI and S3 lack such a codon, their potential 
expression in EIAV-infected cells would require the in-frame splicing of an 
initiator codon from an upstream reading frame. The results of our SI nuclease 
mapping experiments point to the existence of at least one double-spliced mRNA 
in EIAV-infected FDD cells whose first exon contains the 5’-leader sequences 
upstream of the gag gene, and in its second and third exons it contains the coding 
sequences of SI and S3, respectively. Almost the entire coding sequence of S2, 
with the exception of its first seven codons, is removed from this mRNA by 
splicing, suggesting that potential expression of S2 in virus-infected cells would 
require the existence of a separately spliced mRNA.
Nucleotide sequencing of the splice-junction cDNA of the 3.5-kb mRNA 
had revealed that the splice acceptor site for this mRNA is located 178 
nucleotides upstream of the env gene ATG initiator codon. Because the S2 ATG 
codon is 23 nucleotides upstream of the ATG codon of env, and the coding 
sequences of the two genes are present on the same spliced 3.5-kb mRNA and in 
different reading frames, we postulated that this mRNA could potentially encode 
the S2 gene product in addition to the env proteins. To test the hypothsesis, a 
transcript designed to contain the coding sequences of both S2 and env identical 
to that of the 3.5-kb mRNA was synthesized in vitro and its coding capacity was 
evaluated by in vitro translation.
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The 270-bp Smal-BamYR fragment of the splice junction cDNA, sequenced 
earlier for identification of the splice donor and acceptor sites of the 3.5-kb 
mRNA, was ligated to a 2710-bp BamHl-Pstl fragment containing the remainder 
of the env coding sequence and derived from a separate cDNA clone. The hybrid 
Smal-PstI cDNA fragment, containing the entire coding sequences of both S2 and 
env genes, was then cloned into the in vitro transcription vector pSP65 
downstream of the SP6 promoter (Figure 19). Two separate linear DNA 
templates of the plasmid DNA containing the S2-env cDNA insert were prepared 
for in vitro transcription by SP6 RNA polymerase. One of the linearized templates 
was prepared by digestion of the plasmid with HindUl, an enzyme which cleaves 
the env gene at two unique restriction sites, one at about 300-bp and the other at 
approximately 1030-bp downstream of the S2 coding sequence (Figure 19). The 
second linearized template was prepared by digestion of the plasmid with Mlul, 
an enzyme which cuts at a unique restriction site within the 3’-LTR downstream 
of the env gene (Figure 19). The design of the two linear templates for in vitro 
transcription was based on the premise that if translational initiation from this 
mRNA begins at the ATG codons of both S2 and env, then in vitro translation of 
the truncated transcript generated from the /fr/u/III-linearized template would 
yield a full-length S2 protein and a truncated env protein, while translation of the 
full-length transcript generated from the M/uI-linearized template would yield 
both S2 and env proteins in their full-length forms.
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Figure 19. Construction of the S2-env in vitro transcription vector. The 270-bp 
Smal-BamHl fragment of the splice junction cDNA was ligated to a 2710-bp 
BaniiH-Psil fragment containing the remainder of the env coding sequence and 
derived from a separate cDNA clone. The hybrid Smal-Pstl cDNA fragment, 
containing the entire coding sequences of both S2 and env genes in their natural 
spliced form, was subcloned into pUC19 and taken out as a Sacl-Pstl fragment. 
The 2980-bp Sacl-Pstl S2-env hybrid cDNA was then cloned into the in vitro 
transcription vector pSP65 downstream of the SP6 promoter. The location of the 
HindUl and Mlul restriction sites on the EIAV genome are also indicated.
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The transcripts derived from the two templates were translated in a cell- 
free extract of wheat-germ in the presence of 35S-methionine, and the 35S-labeled 
translational products were fractionated by SDS-polyacrylamide gel electro­
phoresis (SDS-PAGE). The results, presented in Figure 20, indicate that a lower 
molecular weight polypeptide of about 7.5-kda is encoded by both transcripts 
(lanes 1 and 2). Moreover, the longer transcript, generated from the Mlul- 
linearized template, encodes a second protein of about 27.0- to 28.0-kda (lane 1), 
while the second protein expressed by the truncated transcript, produced from the 
///nJHI-linearized template, migrates at about 16.0- to 17.0-kda (lane 2).
Based on the nucleotide sequence of 52 and env, the coding potential of 
these two genes were calculated to be approximately 7.5- and 97.0-kda, 
respectively, from the long transcript. Moreover, the size of the env protein 
translated from the truncated transcript was calculated to be around 17.0-kda.
The translation of the smaller protein from both truncated and full-length 
transcripts and its apparent molecular weight of 7.5-kda, as expected for the 52 
gene product, suggested that it was expressed from the 52 coding sequence in 
both transcripts. Moreover, in the case of the truncated transcript, the larger 
protein exhibited the 17.0-kda electrophoretic mobility expected from the 
truncated env protein (Figure 20, lane 2), whose coding sequence would have had 
ended at the HindUl site. This observation suggested that both 52 and env could 
have been translated from this transcript. However, in the case of the full-length 
transcript, the larger protein exhibited a molecular weight of about 27.0-kda 
(Figure 20, lane 1), much smaller than the 97.0-kda full-length protein expected
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Figure 20. Analysis of the 35S-labeled in vitro translational products of the full- 
length (lane 1) and truncated (lane 2) S2-env in vitro transcript by SDS-PAGE. 
Size markers on the left are the 14C-labeled 3.0- to 43.0-kda molecular weight 
standards from BRL.
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to have been synthesized from the env coding sequences of the full-length 
transcript.
Because most plasmid clones of the full-length EIAV env gene, once 
propogated in E. coli, are very unstable and contain nucleotide deletions, 
insertions, or substitutions (K. Rushlow, unpublished data; see below), it was 
suspected that the env coding sequences within the cDNA insert of the 
transcription vector, from which the full-length transcript had been transcribed, 
had undergone a mutation during the plasmid’s propogation in E. coli. Such 
mutation(s) could have potentially introduced premature termination codon(s) in 
the env coding sequence of the full-length transcript, resulting in prematurely 
terminated env translational products synthesized from this RNA.
To examine this possibility, the env gene of the same plasmid preparation 
used for in vitro synthesis of the truncated and full-length transcripts was 
subjected to nucleotide sequencing (Sanger et al., 1977). The results indicated that 
indeed a deletion had occured within the env coding sequence, 718 nucleotides 
downstream of the env ATG initiation codon (K. Rushlow, personal 
communication; unpublished data). As a result, a C in a CCT (proline) codon had 
been deleted, bringing a TGA termination codon located at 748 nucleotides 
downstream of the env ATG codon (30 nucleotides downstream of the mutation) 
in frame with the env coding sequence and thus terminating translation. In the 
wild-type env sequence, this TGA codon is located in the +1 frame relative to 
the env reading frame, thus it does not function to terminate the translation of 
the wild-type env mRNA.
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The expected molecular weight of the terminated env protein, translated 
from the mutated full-length env transcript, was then calculated and found to be
27.5-kda, a value matching the observed size of the larger protein translated from 
the full-length transcript (Figure 20, lane 1). Thus in vitro translation of 
transcripts containing the coding sequences of both S2 and env gives rise to two 
distinct proteins having the sizes expected of the gene products of these two 
genes, suggesting that translational initiation can occur from each gene’s AUG 
codon on the same mRNA. That the two proteins are indeed encoded by env and 
S2 have been confirmed by immunoprecipitation analysis of the in vitro 
translational products. Polyclonal or monoclonal antibodies against the ELAV 
outer envelope glycoprotein, gp90, and a rabbit polyclonal antibody against a 
synthetic peptide containing amino acid sequences of S2 have been used in 
immunoprecipitation analyses of the translational products. The results indicate 
that the individual large and small proteins expressed from the in vitro transcripts 
described above are recognized by the anti-gp90 and anti-S2 antibodies, 
respectively (R.L. Schiltz, unpublished data).
To examine whether the co-expression of env and S2 proteins from the 
same mRNA, which was observed in vitro, can also be shown in vivo, the 
expression of the two proteins was investigated by utilizing a eukaryotic transient 
expression vector, p91023(B), and a simian cell line, COS-7. In addition to having 
the prokaryotic origin of replication of plasmid pBR322, the p91023(B) eukaryotic 
expression vector (Figure 21) contains the origin of replication derived from the 
small DNA tumor virus, simian virus 40 (SV40). Moreover, COS-7 cells are
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African green monkey cells which have been transformed by an origin of 
replication-defective mutant of SV40 and constitutively express high levels of the 
SV40 large T antigen, a viral protein required for initiation of SV40 DNA 
synthesis from the SV40 origin of replication (Gluzman, 1981; Cullen, 1987). Thus 
the p91023(B) plasmid, once introduced into COS-7 cells, can replicate to a very 
high copy number in these cells and efficiently express the protein products of the 
cloned gene of interest.
As mentioned previously, most plasmid clones of the full-length EIAV env 
gene, once propogated in E. coli, are very unstable and contain nucleotide 
deletions, insertions, or substitutions. It is believed that a stretch of nucleotides 
near the 5’-terminus of the env gene, containing a sequence very similar to that of 
the prokaryotic ribosome binding site (Shine and Dalgamo, 1975), causes cryptic 
or "leaky" expression of the env gene in bacteria which harbor plasmids containing 
the env coding sequences (K. Rushlow, unpublished data). The expressed env 
proteins, most possibly toxic to the bacteria, result in aberrant cell growth 
patterns such as extremely slow growth in liquid cultures or small colony 
morphology on solid media. Those bacterial clones which grow normally or 
exhibit a wild-type phenotype, however, are usually selected for by mutations in 
the env gene which block the full expression of env. This phenomenon was 
documented earlier by the recombinant pSP65 in vitro transcription vector, 
containing the full-length S2-env sequence, which had expressed a truncated env
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Figure 21. The eukaryotic transient expression vector p91023(B) (Kaufman et a l, 
1985; Wong et al., 1985; Sambrook and Gething, 1988). The vector contains the 
pBR322 prokaryotic origin of replication and tetracycline resistance gene, but 
lacks the "poison" sequences of pBR322 which have been claimed to inhibit DNA 
replication in eukaryotic cells (Luskey and Botchan, 1981). In addition, the vector 
contains the following eukaryotic regulatory elements: 1) the SV40 origin of 
replication and enhancer; 2) the adenovirus major late promoter coupled to a 
cDNA copy of the adenovirus tripartite leader; 3) a hybrid intron consisting of 
splice donor site from the first exon of the tripartite leader and a splice acceptor 
site from a mouse immunoglobulin gene; 4) the SV40 polyadenylation signal; 5) 
the adenovirus VAI and VAII genes. The vector also contains the mouse 
dihydrofolate reductase (DHFR) coding sequence immediately downstream of the 
unique EcoRI cloning site. Both the cloned DNA and the DHFR gene lie within 
the same transcription unit, allowing the transcription of a dicistronic mRNA and 
translation of the DHFR coding sequence from the 3’-proximal open reading 
frame of the dicistronic transcript. In addition, the DHFR gene serves to provide 
a marker for selection and amplification of the vector DNA in transformed cells 
(Sambrook and Gething, 1988). The adenovirus tripartite leader and the VA 
RNA’s have been proposed to increse the efficiency with which polycistronic 
mRNA’s are translated (Logan and Shenk, 1984; Kaufman, 1985).
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protein as a result of a single nucleotide deletion, and has also been observed 
and documented in a variety of EIAV env subclones (K. Rushlow, personal 
communication).
To assess the potential of the single-spliced EIAV env mRNA to encode 
both env and 52 proteins in vivo, the 2980-bp hybrid cDNA, previously cloned 
into the pSP65 in vitro transcription vector and containing the coding sequences 
of both env and S2, was cloned into the p91023(B) vector and propogated in E. 
coli. All attempts for recovering a recombinant clone containing the full-length 
cDNA insert were unsuccessfull, as all recombinant plasmids contained large 
deletions, presumably within the env gene. These observations were not 
surprising, in light of the problems mentioned above regarding plasmids harboring 
full-length EIAV env sequences. These problems are complicated even further 
due to the presence of an elaborate series of prokaryotic and eukaryotic 
regulatory elements within the p91023(B) expression vector (see below) which 
probably enhance the cryptic expression of the cloned EIAV env sequences when 
the plasmid is propogated in E. coli.
To obtain a functional expression plasmid lacking major deletions in the 
env gene, a 426-bp Sspl-Smal fragment of the EIAV provirus, starting at 21 
nucleotides upstream of the S2 ATG codon and extending for 379 nucleotides 
downstream of the env ATG codon, was cloned into the p91023(B) vector. The 
recombinant plasmid, designated p9SR426 and containing the entire S2 
coding sequence followed by the 5’-terminal 379 nucleotides of env, was then 
expected to encode the 7.5-kda 52 protein and an approximately 14.0-kda amino-
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terminal env protein in transfected COS-7 cells, assuming the in vivo expression of 
both S2 and env from the same mRNA. Restriction enzyme mapping of 
recombinant p9SR426 plasmid DNA from many individual clones had indicated 
that the full-length 426-bp insert was present within the plasmid (data not shown). 
Thus the putative p9SR426 expression plasmid was transfected into COS-7 cells 
for an assessment of its ability to express both the S2 and env coding sequences.
To date no function has been associated with the putative EIAV S2 
protein. Therefore detection of any expressed S2 protein in COS-7 cells 
transfected with the p9SR426 expression plasmid could not be based on a 
functional assay. Instead, assays for detection of S2 and the amino-terminal env 
protein, both of which could potentially be expressed from the expression 
plasmid, were based on immunological detection methods.
The EIAV env gene, 2578 nucleotides long, codes for the viral envelope 
and transmembrane glycoproteins (gp90 and gp45, respectively; Rushlow et al., 
1986). Starting from the 5’-end of env, the first 1330 nucleotides code for gp90, 
while its latter 1248 nucleotides code for gp45. The env coding sequences present 
in p9SR426, as mentioned previously, contain the first 379 nucleotides of env.
Thus the expressed env protein product of p9SR426 should be the amino-terminal 
126 amino acids of gp90.
As an initial approach for detection of the expressed protein products of 
p9SR426 in COS-7 cells, indirect immunofluorescence microscopy was used. As 
primary antibody for detection of the putative env protein, a monoclonal antibody 
recognizing an epitope in the amino-terminal region of gp90 was used. On the
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other hand, the primary antibody used for detection of the putative 52 protein 
was a rabbit polyclonal antibody raised against a 36-residue synthetic peptide 
derived from the sequences of S2. Each primary antibody was reacted with a 
separate preparation of COS-7 cells transfected with p9SR426. Subsequently, the 
cells were incubated with fluorescein-conjugated goat anti-mouse (in the case of 
anti-gp90 monoclonal antibody) or goat anti-rabbit IgG (in the case of anti-52 
polyclonal antibody), and examined under UV light. As shown in Figure 22, high 
level expression of the env coding sequence of p9SR426 can be clearly observed 
in 4-6% of COS-7 cells transfected with this plasmid, the percentage of cells 
expected to have incorporated the plasmid DNA. The expression of 52 in 
p9SR426-transfected cells, however, is not as clearly observed (Figure 23), 
although faint yellow-green fluorescent areas can be detected within the cell 
population examined. The high level of observed background fluorescence is due 
to the polyclonal nature of the anti-52 antibody, making it difficult to distinguish 
positive fluorescent cells from the background of non-specific fluorescence.
To better detect the putative expression of 52 from p9SR426 in transfected 
COS-7 cells, an alternative approach was taken. Following transfection with 
p9SR426, COS-7 cells were labeled with 35S-methionine and -cysteine. The 
cellular extract was then immunopredpitated using the anti-52 polyclonal 
antibody described above, the predpitated products were fractionated by SDS- 
polyacrylamide gel eledrophoresis, and they were deteded by autoradiography. 
The results, however, indicated no detectable levels of the 52 protein (data not
Figure 22. Immunofluorescence photographs of fixed p9SR426-transfected COS-7 
cell cultures treated with anti-gp90 monoclonal antibody followed by fluorescein- 
conjugated goat anti-mouse IgG.
Figure 23. Immunofluorescence photographs of fixed p9SR426-transfected COS-7 
cell cultures treated with anti-52 rabbit polyclonal antibody followed by 
fluorescein-conjugated goat anti-rabbit IgG.
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shown), suggesting either a low level or a lack of S2 expression in p9SR426- 
transfected COS-7 cells.
The indirect immunofluorescence microscopy technique has allowed us to 
conclude that the env coding sequence of p9SR426 is indeed expressed in COS-7 
cells, although no such conclusion can be made regarding the expression of the S2 
gene from this plasmid. The potential implications of these findings are presented 
in Chapter 4.
CHAPTER 4 
DISCUSSION
The results of the experiments described above have allowed us to 
determine the following:
(1) The number, sizes, and relative levels of the transcripts of EIAV 
encoded during persistent and cytopathic infections of equine cell lines.
(2) Quantitative differences in patterns of EIAV transcription during 
persistent and cytopathic infections.
(3) The splicing patterns of the full-length EIAV mRNA, including the 
splice donor and acceptor sites, used to generate the spliced EIAV mRNA’s in 
virus-infected cells.
(4) A potential mechanism for expression of the viral env proteins and a 
putative regulatory protein from the same single-spliced viral transcript.
The results of the present investigations have indicated that EIAV encodes 
three species of mRNA in infected cells: an 8.2-kb full-length genomic mRNA, a
3.5-kb single-spliced mRNA, and a low abundance 1.5-kb mRNA, presumably 
formed by a double-splicing event of the full-length mRNA. Analysis of the levels 
of EIAV-specific RNA’s present during persistent and cytopathic infections has 
revealed that quantitative differences characterize the transcriptional patterns of 
EIAV in these two infections. In persistently infected FEK cells the 8.2- and 3.5- 
kb transcripts are the predominant viral transcripts and are detected in 
approximately equal concentrations, while the 1.5-kb viral mRNA is detected at
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very low levels. During the cytopathic infection of FDD cells the 3.5-kb mRNA is 
the predominant viral transcript, comprising nearly 75% of the total viral mRNA. 
Moreover, the cytopathic infection is characterized by almost a thirty-fold higher 
level of viral transcripts than those detected during the persistent infection.
It is not known whether the nearly 30-fold higher concentration of viral 
transcripts observed in the cytopathic infection of FDD cells, relative to that in 
persistently infected FEK cells, is a result of more efficient viral transcription or a 
consequence of greater stability of viral RNA’s in infected FDD cells. Moreover, 
the differential transcriptional pattern of EIAV in the two cell-lines examined in 
these investigations suggests the involvement of a cell type-specific regulatory 
mechanism of viral transcription. It is possible that the more efficient splicing of 
the full-length EIAV genomic mRNA to the 3.5-kb env mRNA in infected FDD 
cells is a cell-specific phenomenon resulting from potential interactions between 
certain cellular factor(s) and viral regulatory protein(s). This may in turn affect 
the transcriptional initiation or the stability of the full-length viral mRNA, or the 
efficiency of its transport from the nucleus to the cytoplasm relative to that of the
3.5-kb mRNA. In the case of HTV-1, the fra/u-activator tat protein has already 
been shown to enhance the rate of viral transcription from the 5’-LTR (Jacobovits 
et al., 1988; Laspia et al., 1989), and the trans-acting rev protein has already been 
reported to have a role in transporting the full-length and single-spliced viral 
mRNA’s to the cytoplasm and away from the splicing machinery in the nucleus 
(Felber et al., 1989; Hammarskjold et al., 1989; Malim et al., 1989). Furthermore, 
the enhanced levels of env mRNA in EIAV-infected FDD cells may result in
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higher levels of viral glycoprotein production in these cells, thus contributing to 
the cytopathic effects of the infection. In this regard, high level expression of the 
HIV-1 envelope gene has been shown to have a direct role in syncytium 
formation and cytopathicity (Sodroski et al., 1986).
The transcriptional patterns of the lentivirus full-length mRNA are 
generally believed to be more complex than those of other retroviruses, and 
studies on HIV-1 and visna virus point to the presence of a family of double­
spliced viral mRNA’s, 1.5- to 2.0-kb long, which in general encode a variety of 
tram-acting viral regulatory proteins (Arya et cd., 1985; Rabson et al., 1985; Arya 
and Gallo, 1986; Davis et al., 1987; Vigne et al., 1987; Mazarin et al., 1988; Davis 
and Clements, 1989). Through Northern hybridization analysis of RNA from 
virus-infected cells, reports by separate groups of investigators on the patterns of 
HIV-1 or visna virus transcription in different cell lines have generally revealed 
analogously complex but slightly different findings. For instance, in the continuous 
virus producer human T-cell line H9 (Popovic et al., 1984), which is relatively 
resistant to the cytopathic effects of HIV-1, Arya et al. (1984) have reported the 
presence of four virus-specific RNA’s of 9.4-, 4.2-, 2.0-, and 1.8-kb. On the other 
hand, using the same infected H9 T-cell line, or phytohemagglutinin (PHA)- 
stimulated normal human lymphocytes in which infection by HIV-1 results in 
cytopathic effects and cell death, Rabson et al. (1985) have observed five virus- 
specific RNA’s of 9.1-, 5.5-, 5.0-, 4.3-, and 1.8-kb. Moreover, in the case of 
visna virus, Davis et al. (1987) have reported the presence of viral transcripts of
9.4-, 5.0-, 4.3-, 1.8-, and 1.5-kb in virus-infected primary sheep choroid plexus
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cells, while a separate report by Vigne et al. (1987) has pointed to the presence 
of viral RNA’s of 9.4-, 4.8-, 43-, 3.7-, 1.6-, and 1.2-kb in infected American ovine 
fetal trachea cells. Additionally, Davis et al. (1987) have reported a temporal 
regulation of visna virus transcription in which the smallest viral transcript, the
1.5-kb RNA species, is detected 6 how’s after the other viral transcripts are 
observed. On the other hand, studies by Vigne et al. (1987) have suggested a 
different pattern of temporal regulation of visna virus transcription in which the 
1.2- and 1.6-kb viral RNA’s are detected early after infection (at 24 hours), while 
all RNA’s, including the 1.2- and 1.6-kb species, are observed late (at 72 hours) 
after infection. It is apparent that a determination of lentivirus transcriptional 
patterns by Northern hybridization analysis yields only an approximation of the 
actual mRNA structure. This approximation is partly due to variations in the 
length of the electrophoresis gel used by separate investigators to fractionate the 
viral mRNA’s prior to Northern blotting, resulting in differences in resolution of 
the detected mRNA’s on the blot. Other more vigorous analyses, such as 
determination of mRNA splice junctions by SI nuclease mapping, or isolation and 
sequencing of cDNA clones of such spliced mRNA’s are required before the 
exact structure of lentivirus mRNA’s are determined. In this regard, the 
polymerase chain reaction (PCR) (Mullis and Fallona, 1987; Saiki et al., 1988) 
would be an extremely useful experimental tool for amplification and cloning of 
low abundance spliced viral mRNA’s.
In addition to their complexity, the transcriptional patterns of HIV-1 and 
visna virus have a second characteristic in common which is the expression of the
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family of low molecular weight transcripts of these viruses at concentrations 
equivalent to those of the full-length and single-spliced viral RNA species (Aiya 
et al., 1985; Davis et al., 1987; Muesing et al., 1985; Rabson et al., 1985; Vigne et 
al., 1987). The results of the studies on patterns of EIAV transcription in the 
present studies, however, point to low detectable levels of the double-spliced 1.5- 
kb viral mRNA in cells of equine origin. Whether this observation is due to 
specific differences between the genetic organization of EIAV and the other 
lentiviruses, or is a result of the cell-type specific regulation of viral transcription 
described above remains to be determined. Future studies on the patterns of 
EIAV transcription in cell lines different from those utilized in the present 
studies should provide useful information in this regard.
The results of the SI nuclease mapping experiments in the present 
investigations have confirmed the results obtained through Northern hybridization 
analyses using the splice junction-specific oligonucleotide probes, showing that the 
5’-most splice donor site, immediately upstream of the gag gene, is the common 
donor site to all spliced EIAV mRNA’s. Moreover, in addition to the splice 
acceptor site previously identified by sequencing of splice-junction cDNA 
obtained from the 3.5-kb mRNA, the SI nuclease mapping experiments have 
identified and localized a second splice acceptor site upstream of the env gene, a 
splice donor site immediately downstream of SI, and a splice acceptor site at the 
5’-boundary of S3.
Based on the body of information obtained on the splicing patterns of 
EIAV mRNA’s through the experimental results, the splicing patterns of the
EIAV full-length 8.2-kb mRNA are summarized in Figure 24. The splice donor 
site located immediately upstream of the gag gene, 136-nt from the 5’-boundary of 
the primer binding site for reverse transcription, is the common donor site used 
to generate the first exon of all EIAV spliced mRNA’s (Figure 24C-F). Following 
a single splicing event of the full-length mRNA, by which the donor site at 
position 136 is spliced to the acceptor site at position 1084, the gag-pol intron is 
removed and a 3.5-kb mRNA is produced whose second exon begins at the fourth 
codon of SI (position 1084 of Rushlow et al., 1986), and contains the entire S2 
and env coding sequences (Figure 24C). Direct evidence for the existence of this 
spliced mRNA was already presented by cloning of cDNA primed within the 
coding sequences of the env gene. A second potential single splicing event, 
different than that presented in Figure 24C, is depicted in Figure 24D and would 
involve the splicing of the donor site at position 136 to the acceptor site at 
position 1133. This single-spliced mRNA, while still 3.5-kb long, would have a 
first exon identical to that of the former 3.5-kb mRNA (Figure 24C), while its 
second exon would start following the twentieth codon of SI and would contain 
the entire coding sequences of S2 and env. It should be noted that the results of 
SI nuclease mapping studies, as shown in Figure 17B, indicate that the 3.5-kb 
mRNA utilizing the splice acceptor site at position 1084 (Figure 24C) is more 
abundant than the one using the acceptor site at position 1133 (Figure 24D).
A second splicing event of either or both 3.5-kb mRNA’s, utilizing the 
donor site at position 1256 and the acceptor site at position 3184, would then
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Figure 24. Summary of the splicing patterns of the EIAV full-length mRNA, as 
determined by cDNA cloning and sequencing, Northern hybridization analysis 
using splice donor-specific oligonucleotide probes, and SI nuclease mapping.
A  Schematic diagram of the EIAV genome. B. The full-length, unspliced 8.2-kb 
EIAV mRNA Solid and open triangles represent the location of splice donor and 
acceptor sites on the full-length mRNA, respectively, a. 136 nucleotides 
downstream of position 1, defined here as the 5’-boundary of the primer binding 
site (PBS) (Stephens et al., 1986). b. Based on the numbering system of Rushlow 
et al. (1986). C. The single-spliced 3.5-kb env mRNA The existence of this spliced 
EIAV mRNA in virus-infected FDD cells was documented by cloning and 
sequencing of cDNA primed within the env coding sequences of the viral genome.
D. An alternative single-spliced 3.5-kb mRNA generated by a potential splicing 
event utilizing the acceptor site at position 1133 of env. E and F. Double-spliced 
1.4-kb mRNA’s, either one or both of which may be present in EIAV-infected 
FDD cells.
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remove most of the env coding sequences as a second intron and could potentially 
generate either one or two double-spliced 1.5-kb mRNA’s (Figure 24E and F). 
The first exon of both double-spliced mRNA’s would be identical to that of the 
two single-spliced transcripts. However, their second exon, beginning at 
position 1084 or 1133 (Figure 24E and F, respectively), would contain different 
coding capacities. The mRNA utilizing the acceptor site at position 1084 (Figure 
24E) would retain all but the initial four codons of SI; however, in the case of 
the mRNA utilizing the acceptor site at position 1133 (Figure 24F), the first 
twenty codons of SI would be spliced out and the mRNA would retain only the 
latter thirty codons of SI. Following the UAA translational termination codon of 
SI, both mRNA’s would contain the AUG initiation codon of S2 and its following 
six codons spliced onto the third exon of both mRNA’s at the acceptor site 
located at the 5’-boundary of S3.
Although the SI nuclease mapping data have identified the splice donor 
and acceptor sites used to generate the spliced mRNA’s of EIAV, direct evidence 
for the actual presence of the latter three spliced mRNA’s in EIAV-infected cells, 
as depicted in Figure 24D-F, can only be provided by obtaining their respective 
cDNA clones, similar to that of the 3.5-kb mRNA shown in Figure 24C.
Moreover, it should be noted that only the most abundant viral mRNA’s would 
be expected to be detected by the SI nuclease mapping technique. As mentioned 
previously, other low abundance spliced viral mRNA’s would best be detected by 
amplification techniques such as the PCR.
Recently, a cDNA clone of a double-spliced 1.4-kb EIAV mRNA has been 
isolated from an EIAV-infected feline embryo fibroblast (FEA) cell line (Derse 
et al., 1989). The sequence of the 1.4-kb cDNA indicates that its mRNA copy 
contains three exons. The first exon, containing the R and U5 regions of the 5’- 
LTR and 130 nucleotides of the region preceding the gag gene, is joined to the 
second exon using the splice donor site immediately upstream of the gag AUG 
codon and a splice acceptor site near the 5’-end of SI. The second exon, 
containing SI, is 142 nucleotides long and is joined to the third exon using a 
splice donor site immediately following the SI translational termination codon 
and a splice acceptor site within the env gene at the 5’-boundary of the S3. The 
third exon is 948 nucleotides long and contains S3 followed by the U3 and R 
regions of the 3’-LTR. It is interesting to note that this double-spliced mRNA, 
and the splice donor and acceptor sites used to generate it, are identical to those 
defined by the results of SI nuclease mapping experiments in the present studies 
(Figure 24E), with one exception. The splice donor site at the end of the second 
exon, as identified by our SI mapping experiments, is located at 31 nucleotides 
downstream of the SI termination codon (position 1256 of Rushlow et al., 1986; 
Figure 24E; Table III). However, the sequencing of the cDNA has identified this 
donor site as the one located at 1 nucleotide downstream of the SI termination 
codon (position 1226 of Rushlow et al., 1986; Table III; Derse et al., 1989). It is 
uncertain whether the identification of two different splice donor sites by the two 
separate studies is a result of differential cell type-specific mechanisms which 
control post-transcriptional processing of EIAV mRNA’s in the EIAV-infected
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FDD cells examined in the present studies, relative to the infected FEA cells 
used by Derse et al. (1989).
An additional observation regarding the double-spliced 1.4-kb mRNA 
identified by Derse et al. (1989) is that in this mRNA the S3 sequence, lacking an 
AUG initiation codon, is immediately preceded by the SI termination codon and 
no translational initiation AUG codon is spliced onto the S3 sequence. On the 
other hand, the double-spliced mRNA identified by our SI mapping experiments 
would have the S2 AUG codon near the 3’-end of its second exon spliced onto 
the S3 sequence (Figure 24E). However, this AUG codon would not be spliced in 
frame with the S3 coding sequence, thus leaving S3 without an AUG initiation 
codon. Therefore, in neither double-spliced mRNA does an AUG codon splice in 
frame onto the S3 coding sequence. Whether the S3 gene of EIAV indeed 
encodes a protein product remains to be determined, although serological 
evidence points to the expression of an Si-related protein in EIAV-infected 
horses (J. M. Ball and R. C. Montelaro, unpublished data).
As shown by the results of the present studies, a feature common to the 
spliced mRNA’s of EIAV is that they all use the splice donor site located 
immediately upstream of the gag AUG codon to generate their first exon. This 
splicing pattern of the full-length genomic mRNA, which would generate spliced 
mRNA’s sharing similar 5’-ends, has also been observed in other lentiviruses. SI 
nuclease mapping studies of the 5’-region of visna virus (Vigne et al., 1987) and 
sequencing of cDNA clones obtained from spliced visna virus mRNA’s (Mazarin 
et al., 1988; Davis and Clements, 1989) have indicated that all spliced visna virus
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transcripts use a common donor site located at 188 nucleotides upstream of the 
visna virus gag gene (Sonigo et al., 1985). Moreover, sequencing of cDNA clones 
obtained from the spliced mRNA’s of HTV-1 have revealed that the splice donor 
site located at 45 nucleotides upstream of the HIV-1 gag gene generates the first 
exon of these spliced transcripts (Aiya et al., 1985; Muesing et al., 1985).
The interesting finding regarding the spliced transcripts of EIAV, however, 
is that following such splicing events the gag AUG codon is removed from all 
these mRNA’s. Thus, for instance, in the double-spliced mRNA identified either 
by the present studies or by those of Derse et al. (1989), the SI coding sequence 
located within the second exon of the mRNA lacks an AUG initiation codon. In 
the case of HIV-1 or visna virus, however, the coding sequences of the short 
ORFs encoded by these viruses contain their own AUG codons and their 
translational initiation is not dependant on the splicing of an AUG codon from 
an upstream gene (Arya et al., 1985; Muesing et al., 1985; Mazarin et al., 1988; 
Davis and Clements, 1989). In the case of EIAV, it is proposed that the 
translation of the SI coding sequence on the double-spliced 1.4-kb mRNA is 
initiated from a non-AUG codon (Derse et al., 1989). Although the translational 
mechanism of SI from this mRNA is not fully understood yet, the usage of a non- 
AUG codon for translational initiation of a viral regulatory gene would 
potentially provide an additional control mechanism for fine-tuning of EIAV gene 
regulation not previously observed in other lentiviruses. The first two exons of the 
double-spliced 1.4-kb mRNA identified by Derse et al. (1989) are identical to the 
first two exons of the single-spliced 3.5-kb env mRNA identified in the present
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studies (Figure 24C). Therefore it is plausible to assume that 52, 52, and env 
genes could all be expressed from this single-spliced mRNA. If this phenomenon 
indeed occurs in vivo, the efficient expression of the distal 52 and env genes 
would require that the proximal 52 coding sequence be poorly expressed. The 
utilization of a non-AUG codon, which might be poorly utilized and frequently 
passed over by the ribosomes, would potentially provide such a control 
mechanism for translation of 52 (Derse et al., 1989).
The results of the present investigations on the co-expression of 52 and env 
from the same transcript indicate that expression of both proteins from the same 
transcript can be detected in vitro. Studies on the in vivo expression of the two 
proteins, however, have not been as conclusive. Although expression of the env 
gene from a proviral DNA fragment containing the ATG codons of both 52 and 
env can be clearly demonstrated in transfected COS-7 cells, no such conclusion 
can be made regarding the expression of 52.
It is possible that the 52 protein is indeed not expressed in these cells. 
However, this lack of 52 detection, based solely on results of immunological 
detecton methods, could also be due to other factors. It is possible, for instance, 
that the anti-52 titer of the polyclonal antibody is perhaps insufficient to detect 
any expressed protein in these experiments. In addition, as mentioned before, the 
length of the 5’-upstream sequences of the 52 gene in the p9SR426 expression 
plasmid have been minimized to avoid the problems associated with cloning of 
the env gene. It is possible that additional 5’-untranslated sequences, not present 
in p9SR426, are required for efficient translation of the 52 reading frame.
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An interesting possibility is that the in vivo expression of the EIAV 52 
gene occurs at a much lower frequency relative to that of a structural viral gene 
such as env, making the 52 protein difficult to detect. In this regard, it should be 
noted that the nucleotide sequence surrounding the 52 AUG codon does not 
constitute a favorable context for translational initiation at this AUG, as defined 
by Kozak (1986a and 1986b). The sequence of nucleotides around the 52 AUG 
codon is GAUAUAUGG (Rushlow et al., 1986), while the AUG sequence context 
for optimal translational initiation is defined as CCACCAUGG (Kozak, 1986b). 
On the other hand, the env AUG codon, present in a GUAACAUGG sequence 
context (Rushlow et al., 1986), is much more favored for tanslational initiation. It 
has been suggested that positions -3 and +4 in this sequence context, where the 
"A" nucleotide of the AUG triplet is defined as the +1 position, are especially 
critical; the presence of a pyrimidine instead of a purine at these two positions 
can reduce the frequency of translational initiation by 5- to 10-fold (Kozak, 
1986a). It is interesting to note that the 52 AUG contains a pyrimidine at the -3 
position, while the env AUG contains a purine. This suggests that if indeed 
translational initiation does occur from the 52 AUG in vivo, it would happen 
much less frequently than from the env AUG. In the in vitro analysis of 52 and 
env expression in a wheat-germ extract, however, it was observed that higher 
levels of 52 were synthesized relative to env (Figure 20, lanes 1 and 2). In this 
regard, it should be noted that in the wheat-germ system translational initiation 
occurs much more efficiently from the 5’-most AUG codon (D. Shih, personal 
communication), which in this case is that of 52.
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Taken together with the model of infrequent SI translation from a non- 
AUG codon, as discussed above, it is plausible to propose that Si, S2, and env 
could all be potentially expressed from the 3.5-kb env transcript of EIAV. The 
virus can then be assumed to have evolved the following fine-tuning mechanism 
to insure optimal expression of the structural env gene located distal to the 5’-end 
of the 3.5-kb mRNA. The first two genes (Si and S2) would be inefficiently 
translated from a non-AUG codon and an AUG codon in a non-optimal 
sequence context, respectively, while a majority of the ribosomes initiate 
translation from the env AUG codon, resulting in efficient synthesis of the viral 
envelope proteins.
The co-expression of more than one viral protein from the same mRNA 
has been observed in many different animal virus systems, including retroviruses 
such as HTLV-I (Nagashima et al., 1986), HTLV-II (Shimotohno et al., 1985), 
BLV (Rice et al., 1987), and HIV-1 (Arya and Gallo, 1986; Sodroski et al., 1986). 
An ideal means of detecting the potential expression of the 52 gene from the 
expression plasmid p9SR426 used in the present studies would be based on a 
functional assay by which the function encoded by 52 could be assayed in 
transfected cells. Design of such functional assays, however, await the assignment 
of a specific function to the putative EIAV 52 protein.
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